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ABSTRACT 
 
 Reagents that bind proteins are applicable in biology for detection of molecules, 
perturbation of signaling pathways and development of small-molecule pharmaceuticals. 
Protein ligands interact with proteins, inhibiting or altering their function. They are isolated 
from combinatorial libraries to interact with a specific target, using selection techniques such as 
phage display or yeast-two-hybrid assay. For the latter, one inconvenience is the detection of 
false positives, which can be solved by screening pools containing the samples to be tested, 
instead of individual samples. Samples are distributed in the pools following a pooling design. 
The PI-deconvolution pooling design was developed to screen cDNA libraries using the yeast-
two-hybrid assay, which are smaller in size than protein ligand combinatorial libraries. 
Modifications to the PI-deconvolution screening technique were developed to adapt it to the 
screening of protein ligand combinatorial libraries using the yeast-two-hybrid assay. Every spot 
of the array containing the combinatorial library was randomly pooled. However, the yeast-
two-hybrid assay loses sensitivity when strains are pooled. As PI-deconvolution requires 
detecting every interaction, we determined the optimal amount of library members that can be 
pooled in a spot, and the optimal number of replicates to ensure the detection of an interaction.  
 The yeast-two-hybrid assay was used to perform a screening of a combinatorial library 
with seven domains of BCR-ABL, which were pooled according to PI-deconvolution. BCR-
ABL is a chimeric protein with unregulated kinase activity that is responsible for chronic 
myelogenous leukemia. The scaffold used in the combinatorial library was an engineered intein 
that forms lariat peptides. After a screening of this library was performed, positive interactions 
were detected in 775 spots of the arrays that contained 1432 positive hits. Only 53 spots were 
deconvoluted. The coding sequences of the lariat peptides were determined for 23 lariat 
peptides interacted with the GEF domain of BCR, and for ABL, two with the FABD domain, 
one with the SH1 domain, and one with the SH3 domain. Finally, a β-galactosidase assay was 
performed to assess the affinity of the lariat peptides for their target.  
 The isolated lariat peptides are potential inhibitors of BCR-ABL that can have 
therapeutic potential. This study will improve other screenings of combinatorial libraries with 
the yeast-two-hybrid assay.  
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1. INTRODUCTION 
 
 Antibodies are the most widely used protein ligands for biotechnology applications, 
including immunoprecipitation, immunohistochemistry, bioseparation, diagnostics, protein 
chips, ELISA, and therapeutics. However, because of their large size and the requirement of 
disulfide bonds to preserve their structure they are not suitable for intracellular applications 
(Nygren and Skerra, 2004). Artificially developed molecules can be developed as alternatives 
to antibodies, after advances have been made to generate functional diversity and screening 
methods.  
 Protein ligands are proteins that physically interact with molecules. They are isolated 
from protein libraries, for which variants that bind the desired targets are selected using 
common approaches that detect protein-protein interactions, such as phage display and yeast-
two-hybrid assay. Screening a protein library using the yeast-two-hybrid assay presents 
limitations, since some of the interactions detected with this assay are false. This makes it 
necessary to reconfirm the detected interactions, through a process that involves a second yeast-
two-hybrid assay with plasmids isolated separately (Geyer and Brent, 2000). This is a time-
consuming and labour-intensive task, which would be preferably avoided. 
 Areas of biology that commonly screen libraries employ pooling of samples. It suggests 
testing mixtures of samples or members from a library, called pools, instead of analyzing 
individual samples. The distribution of library members in the pools is dictated by a pooling 
design. Each pooling design offers different benefits, such as reduction of the number of tests, 
test automation, and detection of false positives in the yeast-two-hybrid assay (Thierry-Mieg, 
2006).  
 The PI-deconvolution pooling design was recently developed for the screening of cDNA 
libraries using the yeast-two-hybrid assay (Jin et al., 2006). In PI-deconvolution, the entire 
library or the targets that will be screened are pooled into pairs. For every pair, half of the 
targets are placed in one pool (named positive), and the remaining half in another pool (named 
negative). The distribution of the library members or targets across the pairs is shuffled for 
every pair. Overall, a specific code, formed by a positive hit present in the positive or negative 
pool of every pair, can be assigned to every target or library member that was pooled and 
tested. When tests are performed for every pool versus an array of protein ligands, positive 
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interactions are deconvoluted to a specific code (a string of plus or minuses, every pair has a ‘+’ 
or ‘−’ outcome), which corresponds to a specific bait. As PI-deconvolution tests for a yeast-
two-hybrid interaction several times, and confirms that an interaction in a pool is not detected if 
a target is not present, it avoids the detection of false negatives and false positives. 
 In this study, PI-deconvolution was employed to screen combinatorial protein ligand 
libraries using the yeast-two-hybrid assay. Optimal conditions to screen a combinatorial protein 
ligand library were determined. Screening of a protein ligand combinatorial library with targets 
pooled according to PI-deconvolution was performed with seven domains of BCR-ABL and a 
negative control (LexA DNA-binding domain). The following domains were screened: Coiled-
Coil (CC), a peptide containing the tyrosine Y177, Guanidine Exchange Factor (GEF), SH3, 
SH2, Tyrosine kinase (SH1) and F-Actin binding domain (FABD). We isolated and sequenced 
protein ligands (that interacted with the GEF domain of BCR and the SH3, SH1 and FABD 
domains of ABL). Finally, we developed a criterion to analyze the output from the screening, 
referred to as deconvolution score. We expect that future screenings of combinatorial protein 
ligand libraries using the yeast-two-hybrid will benefit from the PI-deconvolution pooling 
design and will benefit at different scales, particularly if more targets are screened and robotic 
equipment is employed.   
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2. REVIEW OF THE LITERATURE 
 
2.1. ISOLATION OF PROTEIN LIGANDS 
   
 The extent to which we can understand and control biological systems depends on our 
ability to manipulate the components of the system under study. Proteins are responsible for the 
majority of events that take place in a cell and are the preferred targets for perturbing biological 
systems. One way to alter protein function is to use chemicals that interact specifically with 
proteins. Antibodies produced by the mammalian immune system are an exceptional source of 
proteins that interact with other molecules. They can be isolated to interact against virtually any 
kind of molecule. Antibodies are used in a wide range of applications including therapy, 
studying protein function, diagnostics, bioseparation, and biodetection of molecules. However, 
they cannot be used for intracellular applications and are more adequate for extracellular 
applications. Artificial protein ligands that overcome these limitations can be developed. 
Protein ligands that interact with specific targets are selected by in vitro technologies from large 
protein libraries (106 - 1010 different molecules). Advances in molecular biology have boosted 
research in this field, mainly by improving the generation of protein libraries and 
methodologies that detect protein-protein interactions.  
 
2.1.1. Alternative protein ligands to antibodies 
 Antibodies have been so far the most widely used protein ligands for biotechnology 
applications, such as immunoprecipitations, immunohistochemistry, bioseparation, diagnostics, 
protein chips, ELISAs, and even therapeutic purposes. The region that contains the antigen-
binding site (Fab) is composed of four domains (VH, CH1, VL, CL) that interact with each other 
(Worn and Plückthun, 2001), while the immunological effector function resides in the constant 
region of an antibody (Padlan, 1994). Although antibodies have evolved during millennia to act 
as the main component of the adaptive immune system, their use is mainly restricted to 
extracellular applications (Nygren and Skerra, 2004). As they form disulfide bonds between the 
light and heavy chains, the stability of antibodies within the cell is affected by the reducing 
 3
intracellular environment, which prevents the formation of these disulfide bonds, and affects 
protein conformational folding (Worn and Pluckthun, 2001). Modifications to the original 
antibody molecule that intend to make it functional in the intracellular environment take 
advantage of the modularity of the antigen-binding site. The antigen binding ability of an 
antibody is conserved even when only the VH and VL domains are present. These two domains 
can either be associated non-covalently (Fv fragment) (Skerra and Plückthun, 1988), connected 
by a peptide linker (scFv) (Bird et al.., 1988), a disulfide bond (dsFv) (Glockshuber et al., 
1990; Brinkmann et al., 1993), or both (sc-dsFv) (Young et al., 1995). These modifications to 
the original antibody molecule have been shown to bind targets intracellularly and have been 
used as therapeutic agents and for validation of potential drug targets (Lobato and Rabbits, 
2004).  
 Another alternative is to develop ligand molecules that are not based on the antibody 
molecule. Early attempts to develop ligands based on linear peptides did not prove to be the 
best choice. Linear peptides that interact with proteins do not show high affinity and cannot be 
isolated for the majority of targets screened (Ladner, 1995). Advances made in molecular 
biology and combinatorial chemistry to generate functional diversity and screening methods 
have boosted the development of novel protein ligands with promising applications.  
 
2.1.2. Scaffold engineering 
 Scaffold engineering can be understood as grafting or integrating an affinity function 
into the structural framework of a stably folded protein with suitable properties (Nygren and 
Skerra, 2004). As for protein ligands, the scaffold is the support for one or several short amino-
acid regions (7-20aa average) that bind a specific molecule, mainly as a protruding finger, or a 
flat or crevice-like surface (Hosse et al., 2006). The peptide displayed in the scaffold is 
constrained by either embedding the peptide in the surface loop of the scaffold, or by using 
disulfide bonds to generate peptide loops on the surface of a scaffold. Both approaches limit  
flexibility of the peptides. Constrained peptides generally bind tighter due to their limited 
flexibility, which reduces the entropy penalty upon complex formation (Ladner, 1995). For 
example, peptides constrained in the scaffold Thioredoxin A of E. coli can bind between 100- 
and 10,000- fold better than the linear version of the same peptide (Geyer and Brent, 2000). 
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 Different properties are desired in a protein scaffold. The ideal scaffold protein should 
be small (i.e. for chemical synthesis), highly soluble, thermally stable, able to fold 
independently, expressed in large quantities, highly specific, and bind its target with high 
affinity (Nygren and Skerra, 2004; Hose et al., 2006). Different scaffolds are better for isolating 
protein ligands that interact with specific targets. Some scaffolds are better at binding small 
molecules, whereas others are better at binding large protein surfaces. The ideal scenario would 
be to develop a universal library of protein ligands, based on a scaffold that could bind any 
kind of molecular topology, from small molecules to linear peptides to protein surfaces. 
Different protein ligands that could bind an entire genome could be generated, providing an 
invaluable set of tools to understand the molecular mechanisms occurring in the cell. 
Nonetheless, we are far from reaching this point. Applications based on antibodies are still 
positioned at the top of the majority of life sciences applications, whereas many of the novel 
scaffold-type ligands have only been investigated in terms of principal applicability in different 
contexts (Nygren and Skerra, 2004). 
 Two factors are important in the identification of a protein ligand that interacts with an 
specific target (Colas, 2000). The generation of protein libraries and the selection of proteins 
that can bind desired targets. The diversity of a protein library is generated by synthetic means. 
Most protein ligand libraries are based on a synthetic nucleic acid template, such as a plasmid, 
or mRNA; this depends on the selection technique that will be employed. The most common 
approaches to generate diversity in a library include mutagenesis by PCR, chemical synthesis of 
oligonucletides, and exon shuffling. Chemical synthesis of peptides has also been attempted, 
although to a lesser extent. For DNA-based libraries, it is easy to identify the sequence of the 
isolated protein ligands and is possible to amplify them by PCR or growing the plasmid in 
bacteria. This is a significant advantage over libraries based on peptides or small molecules. 
Selection methodologies that detect protein-protein interactions include phage display, the 
yeast-two-hybrid system, or mRNA display, among others. 
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2.1.3. Methodologies for the selection of protein ligands from combinatorial 
libraries 
 Protein ligands are isolated from combinatorial libraries, constituted by several scaffold 
proteins, each one having a different sequence in its binding region (variable region). The most 
popular in vitro methodologies to isolate protein ligands include phage-display, yeast display, 
ribosome, and mRNA display. In phage display, protein ligands are isolated by a strategy that 
involves the coating of the target protein on a plastic surface, followed by exposure to a library 
of combinatorial protein ligands expressed on the surface of a bacteriophage. Subsequently a 
washing step is performed, which removes proteins that do not bind the target, while the 
scaffold proteins that bound the target proteins are retained. This step can be performed several 
times, accompanied by mutagenesis, resulting in the selection of protein ligands with higher 
affinities (Sidhu et al., 2000). One advantage of phage display is that large libraries can be 
screened (up to 1010 members) (Harrison et al., 1996); this holds true for other in vitro selection 
techniques as well. On the other hand, the yeast-two-hybrid system can only survey smaller 
library sizes, in the order of 106 to 107 members, because the transformation efficiency is lower 
in yeast. Nonetheless, if selected protein ligands isolated by in vitro methodologies will be used 
intracellularly, there is no guarantee that the isolated protein ligands will be functional. The 
selection procedure takes place in an oxidizing environment, unlike the reducing one found in 
the cytoplasm and the nucleus (Geyer and Brent, 2000). They can be toxic or acquire a different 
conformation once expressed inside cells. However, phage display is a preferred method if the 
target is a secreted protein or a membrane receptor (Deshayes et al., 2002). 
 
2.1.3.1. Selection of protein ligands from combinatorial libraries using the 
yeast-two-hybrid assay 
 The yeast-two-hybrid assay is an in vivo assay that allows the detection of protein-
protein interactions in vivo. It is based on the separable nature of transcription factors (Causier, 
2004). In a transcription factor, the DNA-binding domain (DBD) acts to localize the protein to 
specific DNA sequences within the genome, whereas the activation domain (AD) contacts the 
transcription machinery to activate gene transcription A transcription factor can be functional 
even when the two domains are not present in the same protein, they only need to be physically 
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linked. Fields and Song (1989) noted that it was possible to reconstitute a transcription factor 
by bringing the DBD and AD of a transcription factor together after fusing each to one of a pair 
of physically interacting proteins (Figure 2.1). Yeast was the organism of choice because it is 
eukaryotic, well studied and relatively easy to manipulate.   
 
 
 
Figure 2.1. Overview of the yeast-two-hybrid assay. 
 
Inside a yeast cell nucleus are expressed the bait, a target protein fused to a LexA DNA-binding 
domain and the prey, a protein ligand fused to the B42 activation domain. If the bait and prey 
interact, a transcription factor is reconstituted with the LexA DNA-binding domain and the B42 
activation domain, inducing the expression of reporter genes such as LEU2 and ADE3 that will 
allow the yeast cells to grow in synthetic media that lacks leucine and adenine, as well as LacZ, 
which causes the colonies to turn blue in the presence of X-Gal. 
  
 The yeast-two-hybrid assay has been used to isolate protein ligands from combinatorial 
libraries against different targets. Its main advantage is its ability to detect protein-protein 
interactions within eukaryotic cells, therefore the interactions detected in yeast cells are very 
likely to be reproduced in mammalian cells (Geyer and Brent, 2000). Hence the isolated protein 
ligands can be used as tools to study cell signaling pathways and validate drug targets, since 
most of them inhibit protein function (Colas et al., 2008). Additionally, the minimal affinity 
detection of the assay lies within the micromolar range, ensuring the isolation of protein ligands 
with high affinity for its targets. Different protein ligands have been isolated using the yeast-
two-hybrid assay that interact with targets as varied as Cdk2 (Colas et al., 1996), Nr-13 
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(Nouvion et al., 2007), the Hepatitis B Virus core protein (Butz et al., 2001), the SH3 domain 
of RasGAP (Pamonsinlapatham et al., 2008) and BCL-6 (Chattopadhyay et al., 2006). 
 The yeast-two-hybrid assay can be used for phenotypic screenings that aim to find a 
protein ligand that causes a specific phenotype, instead of interacting with a particular protein. 
Once the protein ligand that causes the desired phenotype is isolated, it is used as a bait to 
screen a cDNA library. This step allows the identification of the protein responsible for the 
desired phenotype, which can be used to gain insights into biological mechanisms. This 
approach was used to identify proteins and protein-protein interactions involved in the yeast 
mating α-factor response pathway (Geyer and Brent, 1999). In another study, protein ligands 
(peptide aptamers) that inhibited mammalian cell proliferation in vitro were isolated and found 
to interact with Calcineurin (de Chassey et al., 2007). 
 
2.1.3.2. Components of the yeast-two-hybrid assay 
 In order to apply the yeast-two-hybrid assay to the screening of combinatorial of protein 
ligands, three features must be present (Figure 2.1) (Hoppe-Seyler et al., 2004). First, the target 
protein, referred also as bait, must be expressed fused to a LexA DBD. The second feature 
consists of a combinatorial library of protein ligands. The source of diversity are chemically 
synthesized oligonucleotides, that encode codons for all standard twenty amino-acids in a 
variable region of five to twenty amino-acids. Finally, both the bait plasmid and the library (in 
plasmid form) are inserted into yeast strains of opposite mating type (MATa and MATα). The 
transformation of the vector library into the prey yeast strain is the limiting step of the 
generation of the library diversity, since transformations in yeast cells are not as effective as in 
other organisms like E. coli, and a significant part of the original diversity found in the 
oligonucleotides is lost (Geyer and Brent, 2000). 
 One of the yeast strains that will express the fusion proteins contains reporter genes 
under the control of LexA operators, which are expressed as the result of the interaction 
between the prey and the bait, as this leads to a reconstitution of the transcription factor. They 
can be auxotrophic genes, which supply defective metabolic pathways in yeast mutant strains, 
allowing the formation of colonies in culture medium that lacks specific nutrients when the bait 
and prey interact. For example, the yeast strains (both MATa and MATα) used in the assay 
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cannot grow in medium that lacks leucine, because they have a leu2 mutation that impairs their 
ability to produce this amino acid. However, if a bait and a prey that interact with each other are 
expressed, the reconstituted transcription factor will induce the expression of the LEU2 gene 
(under the control of a LexA operator), allowing the cells to grow. Colorimetric reporter genes 
are also used.  
 The gene lacZ is the most widely used (also under the control of a LexA operator). It 
encodes the β-galactosidase protein, which causes colonies to turn blue in the presence of the 
chromogenic substrate 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal). Green 
fluorescent protein (GFP) has been used as well (Fashena et al., 2000). When the two strains 
that carry the bait and the prey are put in contact in rich media (such as YPDA), they will form 
diploids. Diploids express both the bait and the prey fusion proteins. If they interact, reporter 
genes will be expressed, allowing the diploids to grow in auxotrophic media, thus the 
interaction can be tested (Golemis et al., 2001).  
 
 2.1.4. Classification of scaffolds 
 Protein scaffolds developed until this date lie within a framework of defined structures 
and folds (Figure 2.2). Different protein scaffolds have been employed for the development of 
protein ligands that interact with different targets. 
 
2.1.4.1. Scaffolds for the presentation of a single loop 
 Scaffold proteins that present one random peptide loop are the simplest design (Table 
2.1). The binding site for these protein ligands is formed by a short, extended, constrained 
peptide stretch with varying sequence, usually presented as an exposed loop (Nygren and 
Skerra, 2004). It has been suggested that the conformational constraint of the random peptide 
increases its binding affinity by reducing the entropy of binding upon its target (Ladner, 1995). 
This scaffold facilitates library construction since it is only necessary to randomize one section 
of the scaffold, instead of different regions.  
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Figure 2.2. Representative protein scaffolds selected for the development of protein 
ligands.  
 
The binding region of scaffolds A-B consist of  single loops, secondary elements for scaffolds 
C-D and multiple loops that resemble immunoglobulins for scaffolds E-F. The protein 
backbone including α-helices and β-sheets is depicted in purple; straight bars are disulfide 
bonds and the positions subjected to randomization are shown in yellow. The PDB IDs used to 
generate this figure are shown in parenthesis. (A) Kunitz domain (1AAP) (B) Thioredoxin A 
(1XOB) (C) Affibody: Z-domain of protein A (1Q2N) (D) Knottin: cellulose binding domain 
from cellobiohydrolase Cel7A (1CBH) (E) 10th Fibronectin III (1TTG) (F) Anticalin FluA: 
bilin-binding protein (1T0V) with cavity randomization for fluorescein binding.   
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Table 2.1. Examples of validated scaffolds that display the binding site as a single loop. 
 
Name Origin Structure Target Selection method Source
Bovine pancreatic 
trypsin inhibitor 
Human neutrophil 
elastase Phage display
Roberts et al. , 
1992
Alzheimer's amyloid 
beta-protein 
precursor inhibitor 
(APPI)
Human TF.FVIIa 
(tissue factor/factor 
VIIa) complex
Phage display Dennis et al. , 1994
Three monoclonal 
antibodies
E. coli 's 
flagellum 
display
Lu et al. , 1995
Aptamer
Cyclin dependant 
kinase 2 (Cdk2)
Yeast-two-
hybrid assay
Colas et al. , 
1996
Peptamers Staphylococcal nuclease
Small, 
spontaneous 
fold, exposed 
loop on 
surface
Cell division and yeast 
pheromone response 
pathway proteins
Yeast-two-
hybrid assay
Norman et al. , 
1999
Kunitz
Stable, 60 
residues, 3 
disulfide 
bonds
Thioredoxin A 
(TrxA)
Short, highly 
soluble, forms 
constrained 
loop
 
 
2.1.4.2. Scaffolds with structurally variable loops 
 The binding site for this type of scaffold is formed by a number of hyper-variable loops, 
displayed on secondary elements from different regions of the scaffold (Table 2.2). The best 
example is the immunoglobulin antibody molecule, in which the variable light and heavy chain 
domains form a sandwich of two antiparallel β-sheets forming the structurally conserved 
framework (Padlan, 1994). Several variations to the natural antibody have been proposed, as 
well as new scaffolds whose binding site is based on the arrangement of multiple loops.  
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 Table 2.2. Examples of validated scaffolds that display the binding site as variable loops. 
 
Name Origin Structure Target Selection method Source
Bovine 
erythrocyte 
carbonic 
anhydrase 
Lauwereys et 
al. , 1998
TEM-1 and 
BcII β-
lactamases
Conrath, 2001
Neocarzinostatin
Chromoprotein, consists 
of seven beta-strands in 
two sheets forming a β-
sandwich
Testosterone Phage display Heyd et al. , 
2003
New Antigen
Receptor 
(NAR)
Immunoglobulin from 
shark
Two chains, each with a 
variable and five 
constant domains
Gingipain K Phage display
Nuttall et al. , 
2001
Ubiquitin Phage display Koide et al. , 1998
TNF-α mRNA display Xu et al ., 2002
DNA-binding domain 
of human retinoid-X-
receptor alpha 
Two zinc fingers 
protruding from an 
hydrophobic core
ATP mRNA display
Cho & 
Szostak, 2006
Anticalins
Lipocalin fold from 
bilin-binding protein 
(BBP)
Four loops supported by 
a central β-barrel Fluorescein Phage display
Beste et al ., 
1999
Animal 
immunization
FN3 
(Fibronectin 
Type III)
10th domain of 15 
repeating FN3 units 
in human fibronectin 
 β-strands with three 
loops connecting the 
strands at one end of the 
β-sandwich
VHH 
domains
Dromedary heavy 
chain antibodies 
Two pairs of heavy 
chains, only 3 CDRs 
protruding from one 
edge
 
 
2.1.4.3. Scaffolds providing interfaces on secondary structural elements 
 For this type of scaffold, protein-protein interactions are mediated by rigid super-
secondary structures (Table 2.3). The binding surface is large and flat. These structures involve 
several α-helices or β-strands brought together and side chains protruding from two or more of 
these elements form the interface for complex formation with the target protein (Nygren and 
Skerra, 2004). 
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Table 2.3. Examples of validated scaffolds that display the binding site as a secondary 
structure. 
 
Name Origin Structure Target Selection method Source
Affibodies Protein A Three. α-helix bundle module of ~60aa
Taq DNA 
Polymerase, 
human insulin, 
apoliprotein A-1
Phage display Nord et al. , 1995
Ankyrin 
Repeats (AR)
Artificial 
scaffold with a 
consensus 
sequence 
Domains built from 
repeats composed by a β-
turn, two antiparallel α-
helices and a loop 
Maltose-binding 
protein (MBP)
Ribosome 
display
Binz et al. , 
2004
PDZ domain PDZ domain of AF-6
Binding site formed by 
second alpha-helix and 
second beta-strand and a 
carboxylate binding loop
Drl and Ephrin-
B1
Yeast-two-
hybrid assay
Schneider et 
al. , 1999
1ICA29
Insect Defensin 
A
29aa, forms an alpha-
helix and two beta-
strands, stabilized by 
two disulfide bonds
TNF-α and TNF 
receptors Phage display
Zhao et al. , 
2004
Knottins
C-terminal 
CBD domain 
of cellobio 
hydrolase I
Triple stranded anti-
parallel beta-sheet, 
stabilized by a cysteine 
knot 
Bovine alkaline 
phosphatase Phage display
Smith et al. , 
1998
 
 
2.1.4.4. Cyclic peptide ligands 
 Cyclic peptides are independent of a protein scaffold. They are peptide chains whose 
N− and C− termini are linked through a peptide bond, forming a circular chain. For cyclic 
peptides, similarly to peptides embedded in scaffold, the constraint of the peptide increases the 
affinity for its target. Cyclic peptides are resistant to cellular exoproteases, because they do not 
have exposed termini, and are easy to synthesize (Horswill and Benkovic, 2005). Cyclic 
peptides that act as inhibitors of proteins have been found in nature. Some examples include the 
immunosuppressant Cyclosporin and the antimicrobiall θ-defensin-1 (Craik, 2006). Cyclic 
peptides that interact with specific target proteins have been isolated from combinatorial 
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libraries using phage display. In this technique, the peptides are constrained at disulfide bonds 
formed by cysteines at their ends (Giebel et al., 1995; Meyer et al., 2006).  
 New possibilities for the isolation of cyclic peptides that interact with proteins have 
arisen with engineered inteins. Inteins are segments of a protein that are able to excise 
themselves and join the remaining segments (exteins) through a peptide bond (Gogarten, 2002). 
Scott and colleagues (1999) have altered the position of the exteins within an intein, generating 
the ligation of the exteins into a cyclic peptide. This system has been used isolate cyclic 
peptides from combinatorial libraries to interact with a variety of targets such as the Dam 
Methyltransferase (Naumann et al., 2008) and the protease ClpXP (Cheng et al., 2007). 
Nonetheless, it is not possible to isolate cyclic peptides that interact with specific proteins using 
selection systems such as the yeast two-hybrid assay, since there is no N− or C− terminus to 
fuse a transcription activation domain. The yeast-two-hybrid assay allows isolation of protein 
ligands that interact with multiple surfaces of a desired target protein, instead of proteins 
ligands that disrupt an interaction with another protein or a small molecule. The Geyer lab has 
recently developed a novel genetic assay to isolate lariat peptide inhibitors using the yeast two-
hybrid assay. The original intein system that generates cyclic peptides (Scott et al., 1999) has 
been further engineered to halt the cyclic peptide reaction at an intermediate step (Geyer RC, 
unpublished data), which produces a lariat peptide that contains a transcription activation 
domain covalently attached through an amide bond to a lactone-cyclized peptide (Figure 2.3). 
This modification allows the screening of combinatorial libraries of lariat peptides using the 
yeast-two-hybrid assay. 
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Figure 2.3. Engineered intein to isolate cyclic peptides using the yeast-two-hybrid assay.  
 
a) Intein-mediated peptide cyclization. Steps involved in the cyclization reaction. (i) Folded 
active intein catalyzes a N-to-S acyl shift to form a thioester intermediate, which undergoes a 
transesterification reaction with the serine (S) nucleophile to release the IN fragment and 
produce the lariat intermediate. (ii) Asparagine side chain cyclization releases the IC-
hemaglutinin (HA)-B42 activation domain (ACT)-nuclear localization sequence (NLS) and 
generates a peptide cyclized through a lactone linkage. The lactone undergoes an energetically 
favoured rearrangement to form the final peptide product cyclized through a lactam linkage. (b) 
Lariat peptide yeast two-hybrid assay. In the yeast two-hybrid assay, if the lariat peptide 
interacts with the target protein, the attached transcription activation domain (ACT) activates 
reporter genes. The lariat intermediate is inhibited from proceeding to the cyclic peptide 
product by blocking the asparagine side chain cyclization reaction in step (ii) using an 
asparagine to alanine mutation. The plasmids encoding the target protein fused to LexA (bait) 
and the lariat peptide are present in different yeast strains; when mated, the resulting diploids 
express the two plasmids and the yeast-two-hybrid assay can be tested.  
 
2.1.5. Applications of protein ligands 
 Protein ligands can serve many purposes. They can be exploited at the intracellular level 
to play important roles in elucidating signaling pathways and validate drug targets. At the 
extracellular level, they play important roles in methodologies such as bioseparation and 
detection of molecules, and they are suitable for proteomic-scale studies (Uhlen, 2008).  
 
 15
2.1.5.1. Protein ligands for manipulation of signaling pathways  
 Protein ligands can be used to study and manipulate signaling pathways. Due to the 
modular nature of proteins signaling pathways are very flexible. Among the proteins involved 
in a signaling pathway adaptor proteins mediate specific protein-protein interactions. It also 
means they can be broadly manipulated, which has been documented in cases of pathogenic 
proteins that have acquired the capacity to mediate ectopic protein-protein interactions, such as 
the E6 protein of Human Papilloma Virus (HPV) and the TIR protein from enteropathogenic E. 
coli (Pawson and Warner, 2007). Altered adaptor proteins have also been observed in 
oncogenes, especially in the case of chromosomal aberrations, such as BCR-ABL, a chimera 
that possesses unregulated kinase activity and access to new interaction domains (Ren, 2005). 
Artificial re-wiring or manipulation of signaling pathways has been achieved. Howard et al. 
(2003) created artificial adaptors that joined two different signaling pathways, one apoptotic 
(apoptosis by death receptors) and the other pathway involved in cell growth, differentiation 
and survival (i.e. the Ras-mitogen-activated protein (MAP) kinase/PI 30-kinase pathways). In 
particular, the Fas-associated death domain (FADD) links receptors such as Fas to caspase-
8/10, and thus links them to apoptotic pathways. On the other hand, the SH2 or 
phosphotyrosine-binding (PTB) domains of the GRB2 or SHCA adaptor proteins couple 
tyrosine kinases to signaling pathways involved in cell growth, differentiation, and survival. 
The chimeric proteins DED-SH2 or DED-PTB were found to complex with caspases and were 
recruited to activated receptor tyrosine kinases. This resulted in caspase activation, likely as a 
consequence of clustering of the receptor-associated complex, therefore in cell death (Pawson 
and Warner, 2007). Protein ligands can be used as adaptors that could integrate any protein into 
a desired signaling pathway, as a chimeric protein fused to domains with enzymatic activity or 
other adaptors. This opens the possibility to manipulate signaling pathways, and correct 
aberrant signaling that occurs in many diseases.  
 Another mechanism to manipulate signaling pathways involves translocation of target 
proteins. Colas et al. (2000) expressed protein ligands (peptide aptamers) with affinity for 
CDK2 as fusions to functional domains, to modify and transport CDK2. In particular, the 
CDK2-interacting TRXA protein ligand was fused to a hect domain from ubiquitin-ligases, in 
order to form a complex with ubiquitin ligase to target proteins for degradation. It was shown 
that CDK2 is effectively ubiquitinated by the aptamer chimera, although this modification did 
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not target the protein for degradation. Furthermore, the authors also showed that an anti-CDK2 
aptamer fused to a nuclear-localization-signal (NLS) could transport CDK2 into the nucleus. 
 
2.1.5.2. Protein ligands for validation of drug targets 
 The discovery of new drugs has become a major challenge for the pharmaceutical 
industry, and many potential pharmaceuticals do not pass clinical trials. Despite major 
achievements in biomedical sciences and biotechnology, fewer drugs are currently introduced 
to the market than twenty years ago (Kola and Landis, 2004). This trend can be attributed to 
lack of efficacy and excessive toxicity of the isolated compounds. Criteria to select target 
proteins for therapeutic intervention have been based on experimental results from studies using 
gene knock-outs or downregulation of protein expression. These approaches mainly abolish the 
entire repertoire of functions of the protein. Perturbation of target proteins can be better 
achieved with protein ligands, as they bind to specific surfaces of a protein, thus inhibiting 
function or blocking essential interactions. Abed et al. (2007) compared the effect of different 
reverse genetic approaches such as gene disruption, dominant negative allele over-expression 
and a protein ligand (a peptide aptamer that interacts with FUR) on the transcriptional network 
regulated by the FUR (ferric uptake regulator) protein of E. coli, used as a case study. This 
protein regulates processes as varied as iron homeostasis, metabolism and stress responses. 
Overall, gene knock-out was found to induce more significant perturbations than the other two 
approaches. This can be explained by the fact that the anti-FUR peptide aptamer and the 
dominant negative only inhibited the DNA binding-dependent activities of FUR but not its 
alternative iron sequestration function (Abed et al., 2007).  
 There is a discrepancy between the perturbations introduced by most target validation 
methods and by therapeutic molecules, resulting in target proteins that are either falsely 
validated or falsely rejected (Baines and Colas, 2006). Pharmaceutical drugs are essentially 
small molecules that interact with a specific surface of a protein, thus altering a specific 
function. This is the same mechanism by which protein ligands exert their function. Therefore 
protein ligands can be used to validate drug targets. First, most of the scaffolds can be 
expressed intracellularly, so it can be determined whether their expression induces the desired 
effect, such as killing cancerous cells. On the other hand, the same protein ligands can be used 
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as leads for the discovery of small molecules. In this manner, a library of small molecules can 
be screened to isolate competitive inhibitors of the interaction between the target protein and 
the protein ligand. A modified version of the yeast-two-hybrid system was employed to isolate 
small-molecule compounds that inhibited the interaction between FKBP12 and transforming 
growth factor beta receptor (TGFβ-R), leading to the discovery of inhibitors of the calcineurin-
dependent signaling in T cells (Joshi et al., 2007).  
 
2.1.5.3. Protein microarrays  
 High-throughput analysis of gene and protein expression is gaining popularity given the 
availability of entire genome sequences and advances in methodologies that allow the detection 
of nucleic acids and proteins. DNA microarrays take the lead in this field, since their protein 
counterpart still presents technical limitations. The majority of protein microarray technologies 
that are based on antibodies perform poorly. Antibodies immobilized on surfaces present 
significant cross-reactivity with other proteins, are not chemically stable, and their binding 
specificity is biased to linear antigens motifs from denatured proteins (Haab et al., 2001). An 
alternative to protein microarrays based on antibodies can be found in protein ligands. A 
scaffold based on human Stefin A (named STM) was developed to be employed in extracellular 
applications (Woodman et al., 2005). The scaffold was engineered to reduce its cross-reactivity 
with other proteins and was inserted a binding site previously shown to bind CDK2, displayed 
on a TRXA aptamer (Colas et al., 1996). The STM scaffold was further mutated to introduce a 
single cysteine residue that allowed the oriented attachment of the scaffold to a gold surface, 
via the exposed sulfhydryl group that forms an S−Au bond (Davis, et al., 2007). Dual-
polarization interferometry was used to detect the interaction between the STMcys+ scaffold and 
Cdk2 from yeast cell lysates with high affinity and specificity, demonstrating the usefulness of 
the scaffold in protein microarray methodologies (Johnson et al., 2008).   
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2.2. POOLING DESIGNS FOR SCREENING OF LIBRARIES  
 
 In biology, a library can be defined as a collection of different molecules in a stable 
form. They can be of any chemical nature, ranging from peptides to cDNA molecules present as 
recombinant DNA. They are maintained as a mixture or in an array. Protein ligands are isolated 
from combinatorial protein libraries, by employing methodologies that are used for large-scale 
selections. These libraries contain proteins that consist of an underlying constant scaffold and a 
randomized variable region that differs among members of the library. A screening, or a 
protein-protein interaction test with all the members of the library, is conducted to detect a 
protein ligand that interacts specifically with a target of interest. Screenings are employed with 
technologies that test for protein-protein interactions such as phage display and the yeast-two-
hybrid assay. In a matrix-based library screening using the yeast-two-hybrid assay, several 
arrays containing the protein library are created, where every spot contains from one to 
hundreds of library members (Figure 2.4). A yeast-two-hybrid assay is performed with the 
target protein against all the spots in the arrays. In this way, all possible combinations are tested 
and a comprehensive coverage of the library is achieved. Nonetheless, this approach is both 
time-consuming and labour-intensive, since thousands of mating operations must be performed 
(Zhong et al., 2003).  
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Figure 2.4. Matrix-based yeast-two-hybrid assay.  
 
An array is formed with yeast colonies expressing a bait or a prey. Every component of the 
array is defined as a spot. For the prey array, every spot contains one to hundreds of different 
library members. The bait array contains a yeast strain expressing a single target protein (bait) 
for each spot. The two arrays are plated into a new array that allows the prey and the bait strain 
to form diploids.  The diploids are then plated to scoring plates in which only the yeast-two-
hybrid positive diploids can grow (where an interaction between the prey and the bait occurs).  
 
2.2.1. Limitations of the yeast-two-hybrid assay 
 When screening a protein library using the yeast-two-hybrid assay, many interactions 
(positive hits or colonies) can be detected. Many of these positive hits are false interactions, 
hence it is necessary to reconfirm the detected interactions by isolating the prey plasmid from 
the positive colonies, reinserting it in a new yeast strain, and performing a second yeast-two-
hybrid assay (Geyer and Brent, 2000). A comparison of studies that aimed to map the 
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interactome of Saccharomyces cerevisiae revealed that many protein interactions were missed. 
For example, among the 1,813 interactions that were identified in three different large-scale 
yeast-two-hybrid screenings, only six interactions are found in common among all three data 
sets (Ito et al., 2000). The discrepancies between the studies might be explained in part because 
they covered different fractions of the interactome, which did not overlap substantially. It is not 
completely understood why the yeast-two-hybrid assay presents such a high degree of both 
false positives and negatives. The inability of the yeast-two-hybrid to detect some physiological 
protein-protein interactions can be attributed to improper folding of fused proteins in the yeast 
cell, proteins not entering the nucleus, or proteins not being post-translationally modified (von 
Mering et al., 2002). There is also difficulty in determining the interaction of proteins that are 
toxic to the cell or proteins that auto-activate the yeast-two-hybrid reporters without an 
interaction with another fused protein.  
 
2.2.2. Pooling and group testing 
 Screening of libraries in different areas of biology seeks a common goal: To locate or 
isolate one member of the library, which can be a protein ligand that interacts with a target 
protein. In genome sequencing projects, genomic libraries are available as recombinant 
fragments of a genome sorted in individual clones. It is often necessary to detect or isolate an 
specific member of a library (i.e. member A). To do so, all the members of the library would 
have to be tested. Instead of testing all the members of the library to determine which one is A, 
it is more efficient to test pools of members. A pool is a mixture of library members, or a 
portion of the library. The goal becomes to detect whether a pool contains A, and from there, 
only the members in the pool that contains A will be tested to determine which one is A. This 
sort of problem can be addressed as a group test, which aims to resolve the status of each 
member of a library using the minimum number of tests applied in parallel (Balding and 
Torney, 1996). To address this issue, the members of the library are distributed into every pool 
according to a pooling design. After testing a set of pools constructed according to a pooling 
design, it should be possible to determine which pools contain the desired member. This way it 
can be identified and retrieved from the original library. Pooling reduces the number of tests, 
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allows for test automation, and addresses the problem of experimental variability (Thierry-
Mieg, 2006). 
 Research in pooling designs has been motivated by genome sequencing projects, which 
store a genome as a library of fragments of recombinant DNA (several kilobases in size) in 
clones. These projects usually retrieve a specific sequence from the library. To identify a 
specific sequence, thousands of clones would have to be analyzed, a process both time-
consuming and labour-intensive. Analyzing different pools of clones by PCR or hybridization is 
significantly more effective than analyzing individual samples, and several pooling designs 
have been developed (Balding et al., 1996). The field of genetics has benefited from the 
pooling of individual samples to several areas, such as genotyping (specifically measuring the 
frequencies of SNPs and microsatellites) and linkage studies (Sham, 2002). 
 
2.2.3. Requirements for pooling in biological systems 
 In order to pool samples for high-throughput screenings, some requirements apply 
(Thierry-Mieg, 2006). The library must be available individually in a tagged form. For 
example, a library of cDNA molecules alone is not exploitable; it must exist as recombinant 
cDNA in separate clones. Furthermore, it must be possible to test a pool of objects in a single 
assay and obtain a positive readout if at least one of the objects is positive. For example, this is 
the case when searching for a specific DNA sequence by PCR in a mixture of molecules.  A 
product will be amplified if at least one of the pooled molecules contains the target sequence. 
Finally, pooling is especially desirable and efficient when the fraction of expected positives is 
small (at most a few percent). There are other factors involved as well. The size of the pools 
imposes a limitation on the construction of pools. Very large pools can affect the detection of 
an object, which depends entirely on the efficiency of the test (Balding et al., 1996). This is 
especially important for yeast-two-hybrid screenings, in which the sensitivity of the test decays 
after more than a hundred strains are pooled.  
 Pooling designs can detect false positives. This is due to the redundancy of the tests, 
since each variable is present in several pools, hence tested many times. Nonetheless, reducing 
experimental variability generally requires testing more pools than the optimal number of pools 
required to identify an object from the library. For most applications, it is necessary to find a 
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balance between the number of pools and detection of experimental variability. Some pooling 
designs are very efficient in terms of numbers of tests but lack the robustness and flexibility 
that most real biological applications require. Others are more adaptable and noise-tolerant but 
require the testing of a larger number of pools (Thierry-Mieg, 2006).  
 
2.2.4. Classification of pooling designs  
 One of the most basic pooling designs is the grid design (Figure 2.5). If the library is 
present in an array format, the pools are constructed according to the rows and columns of the 
array. The library members from one column are mixed into one pool, and another pool is 
constructed with the library members of the next column, and so on. Later the pools are tested 
for the presence of a specific library member (Balding et al., 1996). A positive library member 
in the array is detected as the intersection of a positive row pool and a positive column pool. 
However, if more than one positive library member is present in the array, complications can 
arise. This is the case when a positive row pool intersects with a positive column pool from a 
different positive library member. It suggests the detection of a non-existing positive hit
 Pooling designs used in biology are broadly classified as adaptive or non-adaptive group 
tests. In adaptive (multi-stage) group tests, the value of the objects is determined progressively 
after several rounds of tests. The choice of test at any stage depends on the outcomes of 
previous tests (Balding and Torney, 1996). This approach requires fewer tests than non-
adaptive group tests, but it is not suitable for automation since the pools have to be 
reconstructed depending on the outcomes of the previous tests.  
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Figure 2.5. Grid pooling design.  
 
The grid is a simple pooling design. The samples are arrayed on a 96-spot plate (grid) and the 
rows and columns are pooled, creating twenty pools in total. This design is easy to construct 
although it is susceptible to noise and is not efficient in numbers of tests. In our example, two 
samples are positive (black circles: row C, column 3 and row F, column 7), and hence the four 
indicated pools would be positive (bold black letters), in the absence of experimental noise. 
However two samples can be interpreted as positive (row C, column 7 and row F, column 3), 
demanding additional tests to confirm the identity of the samples. 
 
 In non-adaptive group tests, all tests must be specified without knowing the outcomes of 
the other tests (Huang and Weng, 2004). This approach is advantageous because the same pools 
can be tested for all targets and it is automatable. Several non-adaptive pooling designs have 
been proposed, which are more optimal than the grid design and require strong computational 
power to construct the pools and decode the outcomes of the tests. Many approaches have been 
described, which can be broadly classified in two groups, either random or deterministic 
(reviewed in Ngo and Du, 2000; Balding et al., 1996). In the former, some or all of the entries 
are randomly determined with parameterized probabilities, which can be optimized based on 
certain objective function. In deterministic algorithms, the construction of every pool is 
deterministically specified.  
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2.2.5.1. An intuitive  pooling design: PI-Deconvolution 
 An intuitive, non-adaptive transversal pooling design, named PI-deconvolution, deals 
very well with the experimental limitations of the yeast-two-hybrid assay (Jin et al., 2006). In a 
transversal pooling design the pools are divided into separate groups where each group contains 
all the objects of the library (Du et al., 2006). In the original PI-deconvolution pooling design 
targets are pooled instead of the library. Several baits are pooled and screened against a cDNA 
library. Pools are constructed according to n-bit binary codes assigned to 2n baits, ensuring  
every bait is assigned a unique code (Figure 2.6). Every bit of the binary code indicates 
whether a positive hit is present in one of two pools (called pairs), since a specific bait is 
present in only one pool of the pair; for example, bait A will be present in one pool labelled '–' 
but not in the pool labelled '+'. If an interaction occurs in that pair, the bit will be labelled '–'. 
After a screening is performed, a code, which is a string of bits, can be deconvoluted for every 
spot of the array. That code will correspond to a particular bait, since it is known beforehand 
how the pools were constructed, and there is no possibility that one code correspond to more 
than one bait (Jin et al., 2006).   
 In more detail, every pair is constituted by two pools, one referred as positive and the 
remaining one referred as negative, only for nomenclature purposes. In every pair, half of the 
baits are pooled in one pool, and the other half is pooled in the other pool; all baits are included 
in every pair. This process is repeated for every pair, shuffling the baits that are included in the 
positive or negative pool. A yeast-two-hybrid assay is performed with all pools, mating them 
with the arrays that contain the library. A positive interaction of a prey with a bait can be 
detected only in the negative or the positive pair. When these readouts are read along with the 
other pairs, a code is deconvoluted, which must correspond to a specific bait (Jin et al., 2006). 
For example, bait SH3 has been assigned a code '+ – –', and pooled accordingly (Figure 2.6). 
At bit (or pair) 1, denoted by a '+' symbol, bait SH3 is present only in the '+' pool, and the 
positive interaction is only detected in that pool, not in the '–' pool.  
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a)  
 
Pair Pool Baits
1 2 3 + LexA, CC, GEF, SH3
LexA + + + - SH2, SH1, FABD, Y177
CC(aa1-72) + + - + LexA, CC, SH2, SH1
GEF + - + - GEF, SH3, FABD, Y177
SH3 + - - + LexA, GEF, SH2, FABD
SH2 - + + - CC, SH3, SH1, Y177
SH1 - + -
FABD - - +
Y177 - - -
3
Code
Bait 
1
2
 
 
b) 
 
 
Figure 2.6. PI-deconvolution pooling design. 
 
A set of eight baits are pooled into three different pairs. Each bait is assigned a unique code of 
three bits (nnn). b) Yeast-two-hybrid array screening of a lariat combinatorial library by 
PI-deconvolution. The ‘+ – –’ profile (squares) allows deconvolution of a single bait (SH3 
domain of ABL) within a pool of eight baits, whereas the profile ‘+ – +’ (circles) allows 
deconvolution of a single bait (GEF domain of BCR). A positive interaction (hit) is assessed 
when one colony of the array grows and turns blue in sucrose and galactose CSM –HIS –TRP –
ADE –LEU +X-Gal plates. In this particular example, every spot of the array was screened 
against every pool four times. 
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 The efficiency of the approach increases with the number of baits that are pooled. The 
number of baits that can be pooled (2n) increases exponentially, whereas the number of pools 
increases linearly (2n) (Jin et al., 2006). Eight baits are pooled into six pools, sixteen baits are 
pooled into eight pools, thirty-two baits into ten pools, and so on. Additionally, every 
interaction is tested n times, which improves both coverage and accuracy of the data. 
Nonetheless, it is possible to observe ambiguous codes, which arise when a positive interaction 
is detected in the two pools of a pair (false positive), or the opposite case, when no interaction 
is detected in one pair (false negative). In the latter, the code is not deconvolutable to one bait, 
although it narrows down the number of possible baits that were responsible for the interaction.  
 When mapping an interactome, researchers might not be interested in testing more than 
a few baits. If that is the case, pooling the baits according to PI-deconvolution is not the best 
choice. A different approach to the screening of libraries with PI-deconvolution consisted of 
pooling the library instead of pooling the targets (Jin et al., 2007). In their study, an array 
containing ~6,000 preys (expressing cDNAs) from the yeast genome was first divided into 
groups of 16, 32 or 64 preys and then every group was pooled according to PI-deconvolution. 
The arrays were screened against single baits, and the number of interactions detected was 
similar for the three sizes of groups that were pooled, 16, 32 and 64. Pooling a prey array offers 
important benefits, such as reducing by about an order of magnitude the number of plates 
needed to store the array (the original library is contained in sixteen plates of 384 strains each, 
whereas the same library can be contained in three plates using PI-deconvolution with a pool 
size of 32), and the possibility of using the pooled arrays for other projects that involve 
screening of different targets. 
 PI-deconvolution is a very flexible pooling design. Different applications can obtain 
different advantages from every pooling design, depending on factors such as variability of the 
assay, size of the library, expected number of positive hits, and the number of interactions per 
protein. PI-deconvolution was employed to map a transcription factor regulatory network using 
the yeast-one-hybrid assay (in this assay the bait is the promoter region located upstream of the 
reporter genes, which can potentially bind certain transcription factors) is not the best option 
(Vermeirssen et al., 2007).  Deconvolution becomes impossible to solve for baits that interact 
with multiple transcription factors (TFs), because transcription factors that interact with a bait 
could be present in the ‘+’ and ‘−’ pools of a given pair. Furthermore, in yeast-one-hybrid 
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assays many transcription factors can not be detected when diluted more than 27-fold, which 
limits the size of the pools. Although they could adapt the PI-deconvolution pooling design to 
the screening of TF libraries by reducing the pool size and performing parallel screens, as in Jin 
et al. 2007, they developed a very effective design based on Steiner Triple System, a block 
design used in combinatorial mathematics (Vermeirssen et. al., 2007).  
 The PI-deconvolution pooling design is simple and practical. It is very useful for 
applications where sensitivity is compromised, such as the yeast-two-hybrid system, and also 
when the expected number of positive hits is minimal. High numbers of positive hits per pool 
can lead to ambiguous codes, impeding deconvolution. Its principle that one bait has a unique 
distribution among the pools has been exploited by other pooling designs (Thierry-Mieg, 2006). 
More advanced and effective pooling designs have been reported, although the construction of 
the pools is significantly more complex and they need to be decoded with advanced algorithms.  
 
2.2.5.2. PI-deconvolution for the screening of protein ligand combinatorial 
libraries 
 We reasoned that the PI-deconvolution pooling design could be used to screen protein 
ligand combinatorial libraries using the yeast-two-hybrid system, since it shares two features 
with the screening of cDNA libraries: The number of expected positive hits per pool is very low 
(about one hit per one hundred thousand combinatorial prey strains) and false positives are 
encountered. One major difference in the screening of these two types of libraries is the number 
of library members that are screened. Whereas the yeast interactome comprises 6,000 proteins, 
a combinatorial library ideally should comprise more than one million library members to 
ensure the detection of positive hits. The larger the size of the library, the better chances are to 
detect protein ligands for the desired targets. It is very useful to apply PI-deconvolution to the 
screening of combinatorial libraries because several targets can be tested in one run. It presents 
opportunities for development in proteomics and the validation of drug targets. The ability to 
screen many baits at the same time in a high-throughput assay could be used to isolate protein 
ligands for a wide variety of targets, perhaps hundreds, which would be valuable to understand 
deeply how signaling pathways work and the function of specific proteins. Finally, when there 
is interest to determine what domains of a protein are responsible for its pathological activity, 
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or what proteins from a signaling pathway are involved in a disease, it becomes very useful to 
be able to find protein ligands against a variety of targets.      
 In order to apply PI-deconvolution to the screening of combinatorial libraries the 
construction of arrays had to be addressed. Arraying individual strains from a combinatorial 
library is not possible. At least 10,416 96-well plates are needed to array one million strains 
(although it would not ensure a complete coverage of the library, some library members will be 
pooled more than once as well as empty vectors), a quantity that is not achievable for most 
laboratory infrastructures. Therefore, the library we used had to be pooled in order to handle a 
smaller number of plates. However, this would bring sensitivity issues, since the yeast-two-
hybrid assay does not detect interactions when the interacting prey is diluted more than one 
hundred-fold in a pool of non-interacting preys. It became necessary to develop a way to screen 
a condensed combinatorial library in a practical and effective way. The solution to the problem 
was to make pools of the combinatorial library (without any specific distribution) of about 
1,000 yeast cells, so that the arrays could be condensed about 1,000-fold. However, at this 
dilution it is possible to miss a positive hit because there are many other non-interacting strains 
present. Therefore, we decided to test every combinatorial pool of the array four times, an 
empirically validated number of replicates needed to detect at least one positive interaction 
between the combinatorial protein ligand and one of the baits we pooled according to PI-
deconvolution, so a code could be obtained and be deconvoluted to a specific bait.  
 Our combinatorial protein ligand library is based on an engineered intein scaffold that 
produces cyclic peptides intracellularly (Scott et al., 1999). Previous work performed in our lab 
has led to an engineered intein scaffold that displays cyclic peptides that can be linked to the 
yeast-two-hybrid system (through the formation of a lariat peptide to which attach an activation 
domain), allowing the screening of cyclic peptides with this method (Figure 2.3). We screened 
a lariat ligand combinatorial library against a set of seven domains of BCR-ABL and a negative 
control, as a proof of principle for the application of PI-deconvolution to the screening of 
combinatorial libraries using the yeast-two-hybrid system. In addition, protein ligands that 
interact with any of the domains and inhibit the oncogenicity of BCR-ABL would be potential 
candidates for the development of new drugs for the treatment of chronic myelogenous 
leukemia.  
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2.3. ROLE OF BCR-ABL IN CHRONIC MYELOGENOUS LEUKEMIA 
 
2.3.1. Chronic Myelogenous Leukemia and BCR-ABL   
 Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized by 
an excessive production of granulocytic cells (Ren, 2005). The Philadelphia chromosome is 
associated with 95% of CML cases and results from the reciprocal exchange of DNA between 
the long arms of chromosomes nine and twenty-two. This chromosomal aberration produces a 
fusion between the Breakpoint Cluster Region gene (BCR) and the Abelson kinase gene (ABL) 
(Wong and Witte, 2004), named BCR-ABL. ABL tyrosine kinase is tightly regulated in normal 
cells, but in BCR-ABL+ cells it becomes constitutively active and brings new regulatory 
domains/motifs to ABL (Figure 2.7) (Ren, 2005). Other mechanisms by which BCR-ABL 
contributes to the malignant phenotype of myeloid leukemic cells include alteration of the 
adhesion of the hematopoietic stem cell (HSC) to the matrix and stromal cells of the bone 
marrow, activation of mitogenic pathways, like Jak/Stat and Ras/Raf/MAPK, and inhibition of 
apoptotic pathways, such as the PI3K/AKT (Deininger et al., 2000).  
 A milestone in drug discovery has been the development of inhibitors of the kinase 
domain of ABL, which effectively controls the CML disease progression. The first to be 
developed was imatinib, also called gleevec, a compound generated through rational design to 
inhibit the kinase activity of ABL through occupation of its active site (Capdeville et al., 2002). 
However, two problems remain to be solved. First, the drug does not eliminate BCR-ABL+ 
hematopoietic stem cells, therefore the disease is never fully eradicated. On the other hand, 
mutations of BCR-ABL that affect imatinib binding but maintain the kinase activity are likely 
to develop, generating resistance to the drug (Hantschel and Superti-Furga, 2004).  
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Figure 2.7. Structural organization of domains present in BCR-ABL.  
 
The BCR-ABL protein is the result of a fusion between BCR and ABL that results from a 
chromosomal translocation. Specifically, the coiled-coil oligomerization domain plays a role in 
inducing auto-phosphorylation of the kinase. Tyrosine 177 when phosphorylated by BCR-ABL 
can interact with Grb2, activating the Ras signaling pathway. The GEF domain interacts with 
Rac1, Cdc42 and RhoA, suggesting a regulatory role for this interaction. As for ABL, the 
Tyrosine Kinase (Y Kin, SH1 in the text) activates many signaling pathways involved in 
suppression of apoptosis and proliferation. SH3 and SH2 domains are involved in determining 
the structural conformation of the kinase and interact with downstream mediators of cell-
signaling pathways. Proline rich sequences (PxxP) of BCR-ABL can interact with SH3 domains 
and Crkl. BCR-ABL has altered cell-adhesion properties, and also possesses other domains, 
such as Nuclear Localization Domain, DNA-binding domain, and Nuclear-export. Finally in the 
C-terminal region is located an F-actin binding domain (ABD, FABD in the text), which has 
been shown to play a role in suppression of apoptosis. 
 
2.3.2. Domains present in BCR-ABL  
 BCR-ABL is a large chimeric protein. Important domains in BCR include: Coiled-coil 
(CC) domain, serine/threonine kinase domain, Grb2 binding domain (tyrosine 177, Y177), and 
a guanidine-exchange factor (GEF) domain. The coiled-coiled domain induces oligomerization 
of BCR-ABL, which induces autophosphorylation and provides a mechanism for activating the 
ABL kinase (Smith et al., 2003; Hantschel et al., 2004), as well as activates SH2-binding sites 
in BCR for interactions with signaling components such as GRB2 and PI3K (Tauchi et al., 
1997). The serine/threonine kinase domain has an impaired function in BCR-ABL, where it is 
phosphorylated at Tyrosine 360, becoming inactive (Wong and Witte, 2004). The 
phosphorylation of BCR at tyrosine 177 creates an SH2 binding site for GRB2, which in turn 
creates a complex with SOS and GAB2 through its SH3 domains (Ren, 2005). Formation of 
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this complex activates the Ras/MAPK signaling pathway through the activation of RAS by 
SOS. SHP2 and PI3K are further recruited, which in turn activate mitogenic and anti-apoptotic 
pathways (Pendergast et al., 1993; Puil et al., 1994; Sattler et al., 2002).  
 The GEF domain of BCR has homology to several RHO specific GEFs (RhoGEFs), 
including CDC24, DBL, and VAV (Barnes and Melo, 2002). RhoGEFs activate members of the 
Rho family of small GTPases by catalyzing the exchange of GDP for GTP. Rho family 
members are involved in regulation of the actin cytoskeleton (Tapon and Hall, 1997), apoptosis 
(Nishida et al., 1999) and proliferation (Olson et al., 1996). The GEF domain of BCR is 
responsible for the motility of p210 BCR-ABL leukemic cells (Daubons et al., 2008). It also 
activates RHOA (Harnois et al., 2003) and has been shown to interact with XPB, a protein 
associated with increased sensitivity to sunlight and reduced DNA damage repair. This 
interaction reduces the helicase and ATPase activities of XPB (Takeda et al., 1999). 
 As most non-receptor tyrosine kinases, the conformation of ABL is very flexible and its 
kinase activity depends on the conformation of the active site, which can be open (active) or 
closed (inactive) (Hantschel et al., 2004). The SH3 domain of ABL functions as a negative 
regulator of kinase activity in both active and inactive kinase conformations. Interaction of the 
SH3 domain with the SH1 kinase domain keeps ABL in an inactive conformation (Hantschel et 
al., 2003; Barila and Superti-Furga, 1998; Nagar et al., 2003). In the open active kinase 
conformation, the SH3 domain interacts with proteins that negatively regulate kinase activity 
(ABI proteins) (Dai and Pendergast, 1995). Similarly, the SH2 domain of ABL functions as a 
dual regulator of kinase activity in both active and inactive kinase conformations. The SH2 
domain has a positive or negative role depending on the conformation of BCR-ABL. It 
negatively regulates ABL kinase activity by binding to the SH1 domain and maintaining ABL 
in an inactive conformation (Hantschel et al., 2003; Nagar et al., 2003). Additionally, the SH2 
domain contributes to the activation of the RAS pathway through binding SHC, which results in 
phosphorylation and binding of GRB2 (Goga et al., 1995). 
  The tyrosine kinase activity of ABL is the most crucial function for BCR-ABL 
mediated transformation. The SH1 domain has a high degree of homology to the SRC kinase 
domain, although the mechanism of regulation of its kinase activity by its N-terminal domains 
is quite different from SRC regulation (Hantschel and Superti-Furga, 2004); these N-terminal 
domains include N-terminal myristoylation, SH3, and SH2 domains (Van Etten, 1999). 
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Perturbation of these regulatory domains, as is the case in BCR-ABL where the myristoylation 
domain is deleted, results in constitutive activation of the SH1 kinase activity. Numerous 
substrates are tyrosine phosphorylated by BCR-ABL demonstrating the importance of this 
domain in BCR-ABL transformation (Goldman and Melo, 2003; Goss et al., 2006).  
 The last exon of ABL contains many proline-rich domains (PxxP), which function as 
binding sites for SH3 domains of adaptor proteins like CRK, CRKL, GRB2, and NCK (Feller et 
al., 1994; Smith et al., 1999; Sattler et al., 1996). These complexes activate RAS through the 
CRKL/SHC pathway (Oda et al., 1994; Pelicci et al., 1995), which in turn activates mitogenic 
and anti-apoptotic pathways. Furthermore, ABL contains other domains with a variety of 
activities, such as DNA binding, nuclear export (NES) and localization (NLS), and actin 
binding (ABD or FABD). The DNA binding domains (three in total) may be involved in 
initiating transcription, in DNA damage response, and in meiotic processes (Kharbanda et al., 
1998; Yuan et al., 1997; Miao and Wang, 1996). The three nuclear localization signals (NLS) 
and one nuclear export signal (NES) (Taagepera et al., 1998) allow ABL to shuttle between the 
nucleus and cytoplasm in response to various signals. The F-actin binding domain of BCR-
ABL enhances F-actin and cytoskeletal association (Hantschel et al., 2005) and has been shown 
to play a role in suppression of apoptosis (Underhill-Day et al., 2006).   
 
2.3.3. Inhibition of BCR-ABL domains 
 It is better to isolate protein ligands from combinatorial libraries against individual 
domains of a protein, rather than the entire protein. If the entire protein is used, some of the 
surfaces that could bind protein ligands will not be exposed. Secondly, protein ligands might be 
isolated against a specific domain that binds them more easily, generating a bias for specific 
domains. Given its role in CML, BCR-ABL was chosen as a very interesting target for protein 
ligands that inhibit its function. Its many domains could be screened individually at the same 
time using the PI-deconvolution pooling design applied to the screening of combinatorial 
protein ligand libraries. Moreover, the protein ligands isolated against BCR-ABL could inhibit 
the growth of BCR-ABL+ cell lines, validating specific domains as a target for the development 
of small molecule inhibitors. In this way, the isolated protein ligands would serve two 
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functions: Determine which domains are druggable, and lead the development of small 
molecules by competitive binding screenings.   
 The most important domains for BCR-ABL oncogenesis were selected to be used as 
baits in the screening of combinatorial protein ligand libraries using PI-deconvolution pooling 
designs. Only domains that affected the overall structure of ABL kinase (CC, SH3, SH2), were 
involved in signaling pathways (Tyrosine Y177) or possessed specific functions (GEF, FABD) 
were considered, along with the ABL kinase domain (SH1). The remaining domains with less 
important functions, such as the proline-rich regions (PxxP), the DNA-binding domain and the 
Nuclear localization signal were omitted. PI-deconvolution imposes a limit in the number of 
domains that can be pooled, therefore seven BCR-ABL domains were chosen to perform a 
deconvolution screening of a protein ligand combinatorial library using the yeast-two-hybrid 
assay.  
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3. OBJECTIVE 
 
 The overall objective of this study was to adapt the PI-deconvolution pooling design to 
the screening of combinatorial protein ligand libraries using the yeast-two-hybrid assay. 
 
 To achieve this goal, the following steps were undertaken. 
 
1. Cloning of different BCR-ABL domains into a yeast two-hybrid expression vector  
 
2. Determine the conditions necessary to perform a screening of a combinatorial protein ligand 
using the PI-deconvolution pooling design (Jin et al., 2006). 
 
3. Perform a screening of a combinatorial protein ligand library using the PI-deconvolution 
pooling design to isolate lariat ligands that bind to selected BCR-ABL domains using the yeast 
two-hybrid assay.  
 
4. Develop parameters to evaluate the performance of the screening of a combinatorial protein 
ligand library based on PI-deconvolution of the baits. 
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4. MATERIALS AND METHODS 
 
4.1 Common procedures 
 
4.1.1. Cell lines and strains 
 The strain used in the yeast-two-hybrid assay were S. cerevisiae strain EY111 (MATá 
his3 trp1 ura3::URA3-LexA8op-lacZ ade2::URA3-LexA8op-ADE2 leu2::LexA6op-LEU2) and S. 
cerevisiae strain  EY93 (MATa ura2 his3 trp1 leu2 ade2::URA3). The E. coli strain MC 1061 
(Invitrogen) was used for in making multiple copies of the plasmid of interest, and the strain 
BL21 (Stratagene) was used to express proteins of interest.  
 
4.1.2 List of Materials  
 
Table 4.1. Table of reagents used in this study. 
 
Item  Supplier 
Agarose Invitrogen 
Acetic Acid, glacial EMD 
Acrylamide.Bis-Acrylamide [37.5:1] (30%) Bio-Rad 
Adenine Alfa Aesar 
Ammonium persulphate EMD 
Ampicillin, sodium salt Shelton  
Blocking Buffer Li-Cor 
Bromophenol blue Bio-Rad 
Chloroform BDH  
Coomassie Brilliant Blue R-250 Fisher 
Disodium Borate EMD 
Dimethyl formamide Sigma 
Dimethyl sulfoxide (DMSO) Sigma 
dNTP set Fermentas 
Ethidium Bromide BDH  
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Ethyl Alcohol 95% Commercial Alcohols 
EDTA (ethylenediaminetraacetic acid) EM Science 
Glycerol EMD 
Kanamycin sulphate Sigma 
Lithium Acetate Sigma 
Magnesium Sulfate EMD 
2-Mercaptoethanol Sigma 
PEG (Polyethylene Glycol) 8000 EMD 
Phenol:chloforom [1:1] EMD 
Potassium Chloride EMD 
Salmon sperm  Sigma 
Sodium carbonate EMD 
Sodium chloride EMD 
SDS (sodium dodecyl sulfate) EMD 
Sodium Hydroxide BDH 
Sodium Phosphate Dibasic EMD 
Sodium Phosphate EMD 
Synthetic Oligonucleotides Integrated DNA technologies 
TEMED  EM Science 
TRIS [Tris (hydroxymethyl) aminomethane] EMD 
Triton X-100 Sigma 
Trypan Blue Stain  Gibco 
Tween-20 (polyoxyethylene (20) monolaureate sorbitan) EMD 
X-Gal (5-bromo-4chloro-indoyl-β-D-galactopyranoside) Invitrogen 
 
Table 4.2. Table of reagents used in this study. 
 
Item  Supplier 
10X Buffer EcoRI Li-cor 
10X Buffer Taq Polymerase (platinum, high fidelity) Invitrogen 
Anti-LexA antibody  Invitrogen 
Anti-rabbit IRDye 800CW secondary antibody NEB 
EcoRI NEB 
XhoI Invitrogen 
Taq DNA Polymerase (platinum, high fidelity) NEB 
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Table 4.3. Table of reagents used in the preparation of media. 
 
Item Supplier 
Agar BD Biosciences 
CSM, drop out supplements  Biol 101 Inc. 
Dextrose BD Biosciences 
Galactose BD Biosciences 
Peptone BD Biosciences 
Sucrose EMD 
Tryptone BD Biosciences 
Yeast Extract BD Biosciences 
Yeast Nitrogen without Amino Acids BD Biosciences 
 
Table 4.4 Table of reagents used in the preparation of media. 
 
Item  Supplier 
96-1.2ml tube rack Molecular Bioproducts 
Beckman J2-MI Centrifuge Beckman  
Bransonic 220 Ultrasonic Cleaner Branson 
Centrifuge 5810 Eppendorf 
Glass beads, 450-600μm in diameter Sigma 
MaxQ 4000 Shaking Incubator Barnstead 
Microfuge 18 Centrifuge Beckman Coulter 
Micropipettors Gilson 
Micro-pulser Electroporator Bio-Rad 
QIAgen miniprep kit QIAgen 
QIAgen Gel extraction kit QIAgen 
Spectramax 340PC Microplate reader Molecular Devices 
Smartspec 3000 Spectrophotometer Bio-rad 
Ultra-Tech WJ 301D Incubator Baxter 
VP 384F Replicator  V&P Scientific 
VP 408FH Replicator  V&P Scientific 
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 4.2. Molecular biology and common procedures 
  
4.2.1. Polymerase-Chain Reaction (PCR) 
 Plasmid DNA from bacteria was isolated with a commercial kit from QIAgen. Two 
different polymerases were used to serve different purposes. High Fidelity Platinum Taq 
Polymerase (Invitrogen) was used to amplify DNA used in cloning procedures. See Table 4.5 
for the list of primers used for the amplification of BCR-ABL domains and Table 4.6 for the 
amplification of the Ssp-Ssp intein lariat ligand coding region. PCR mixtures in a final volume 
of 50 μL consisted of 0.4 μM of each primer, Buffer 1X, High Fidelity Platinum Taq 
Polymerase (Invitrogen), 1.5 mM MgSO4, 0.2 mM of each dNTP, 1 unit of Platinum Taq DNA 
Polymerase High Fidelity, ~100 pg of plasmid DNA. Taq Polymerase was used to amplify 
DNA fragments by PCR for purposes different from cloning, such as verifying the presence of 
a DNA insert within a vector. It was purified by Kris Barreto according to the protocol 
described by Pluthero (1993). PCR mixtures in a final volume of 50 μL consisted of 0.4 μM of 
each primer, Buffer 1X (10mM Tris-Cl pH 8.3, 50 mM KCl, 1.5 mM MgCl2), 0.2 mM of each 
dNTP, 2.5 U of Taq DNA Polymerase and ~100 pg of plasmid DNA (Ausubel et al., 1988).  
 
Table 4.5. Primers used for cloning of BCR-ABL domains into pEG202 by homologous 
recombination in yeast. 
 
Primer name Sequence (5'-3') Construct  (in pEG202) 
P1 BCR CC  gcg gtt ggg gtt att cgc aac ggc gac tgg ctg gaa ttc atg gtg gac ccg gtg ggc tt 
P2 BCR CC  tcg ccc gga att agc ttg gct gca ggt cga ctc gag ttac cgg tca tag ctc ttc ttt t 
LexA-CC 
P1 BCR Y177 gcg gtt ggg gtt att cgc aac ggc gac tgg ctg gaa ttc gac gcc gag aag ccc ttc 
P2 BCR Y177 tcg ccc gga att agc ttg gct gca ggt cga ctc gag tta aaa ctc gac gtt cac gta 
LexA-Y177 
P1 BCR GEF gcg gtt ggg gtt att cgc aac ggc gac tgg ctg gaa ttc gtc ctg tcg gga atc ctg gc 
P2 BCR GEF tcg ccc gga att agc ttg gct gca ggt cga ctc gag tta att gat gct gga cag gaa gt 
LexA-GEF 
P1 ABL SH1 gcg gtt ggg gtt att cgc aac ggc gac tgg ctg gaa ttc atc acc acg ctc cat tat cc 
P2 ABL SH1  tcg ccc gga att agc ttg gct gca ggt cga ctc gag tta cat tgt ttc aaa ggc ttg gt 
LexA-SH1 
P1 ABL SH2 gcg gtt ggg gtt att cgc aac ggc gac tgg ctg gaa ttc aac agt ctg gag aaa cac tc 
P2 ABL SH2 tcg ccc gga att agc ttg gct gca ggt cga ctc gag tta gtt gcg ctt tgg ggc tgg at 
LexA-SH2 
P1 ABL SH3 gcg gtt ggg gtt att cgc aac ggc gac tgg ctg gaa ttc ctt ttc gtt gca ctg tat ga LexA-SH3 
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P2 ABL SH3 tcg ccc gga att agc ttg gct gca ggt cga ctc gag tta gac tgg cgt gat gta gtt gc 
P1 ABL FABD gcg gtt ggg gtt att cgc aac ggc gac tgg ctg gaa ttc tca acc cga gtg tct ctt cg 
P2 ABL FABD tcg ccc gga att agc ttg gct gca ggt cga ctc gag tta cct ctg cac tat gtc act ga 
LexA-FABD 
  
 For colony-PCR, a sterile plastic tip was used to pick one CFU from the transformed 
cells plated on selective media; the CFU was stirred in 50 μL of PCR reaction and then briefly 
stirred in 5 mL of LB containing the corresponding antibiotic. After the PCR as completed, 
products were visualized on an agarose gel at 1% (w/v) in order to verify the presence of the 
insert of interest in the plasmid. 
 
Table 4.6. Primers used for cloning of lariat ligands into pJG4-5 by homologous 
recombination in yeast and sequence and DNA sequencing 
 
Primer name Sequence (5'-3') 
P1  pJ4-5 pre-EcoRI  tgc gca ccg gac agg aga 
P2  pJG4-5  post-XhoI  gca agg tag aca agc cga caa c 
 
4.2.2. Agarose gel electrophoresis  
 For visualization of DNA, samples were mixed with loading buffer 6X (50% glycerol, 
0.2M EDTA pH 8.3, 0.05% bromophenol blue) to a final concentration of 1X, and 5 μL of the 
mixture were added per lane for PCR products and 1 μL of the mixture for plasmids (50-150 
ng/μL). Samples were resolved on the agarose gel at 200 V for 15 to 30 min on SB Buffer (5 
mM disodium borate decahydrate, pH 8.0), then visualized and photographed using a UV light 
Transilluminator (Bio-Rad). Agarose gels consisted of 0.5 to 1.5% (w/v) agarose (ultrapure 
agarose, Invitrogen), 1X SB Buffer, and 0.5 μg/ml ethidium bromide. For purification of PCR 
products a kit from QIAgen was used.  
 
4.2.3. Transformation of bacterial cells by electroporation 
 The procedure for preparing bacterial cells competent for electroporation is described in 
Ausubel et al., 1988. A colony-forming-unit (CFU) was grow overnight at 37°C in a shaking 
incubator, in 5 mL of LB. The following day, the cells were grown in 500 mL of LB until an 
OD600nm of 0.6 was reached. At that point, the cells were centrifuged at 4,000 rpm for 20 min at 
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4°C and resuspended in ice-cold water. This step was performed twice. The cells were then 
resuspended in 5 mL of ice-cold glycerol 10% (v/v) and aliquots of 50 μL were stored at 
−80°C.  
 Bacterial cells were transformed using electroporation. 1 μL of plasmid (50-150 ng/μL) 
was mixed with 50 μL of competent cells, and the mixture was transferred to an electroporation 
cuvette. Cells were then electroporated with field strength of ~12.5 kV/cm, mixed with 500 μL 
of LB and incubated at 37°C for 30 min in a shaking incubator. Cells were then plated in LB 
agar plates containing ampicillin (100 μg/μL).    
 
4.2.4. DNA sequencing 
 DNA samples were sequenced at the Plant Biotechnology Institute, National Research 
Council of Canada. Plasmids were diluted to 0.05 μg/μL and primers were provided at a 
concentration of 3.2 pmol/μL.   
 
4.2.5. Western Blot of yeast lysates with LexA  
 Cell lysates were prepared following the procedure suggested by Kushnirov, (2000). A 
yeast CFU was grown overnight in CSM −HIS in a shaking incubator at 30°C. Next day, 1 mL 
of the culture was centrifuged for 1 min at 13,000 rpm, and the pellet was resuspended in 100 
μL of ddH2O, followed by the addition of 0.2 M NaOH. The mixture was incubated for 5 min, 
and then centrifuged for 1 min at 13,000 rpm. The pellet was resuspended in 50 μL of SDS 
sample buffer (0.06 M Tris-Cl pH 6.8, 5% Glycerol, 2% SDS, 4% β-mercaptoethanol, 0.0025% 
bromophenol blue) and boiled for 3 min. SDS-PAGE was performed with a 10% acrylamide 
gel, where 10 μL of each cell lysate were loaded per lane. The samples were resolved on the 
acrylamide gel at 200 V for 45 min, and visualized and photographed using a GelDoc imager 
(Bio-Rad). Resolving denaturing gels consisted of 0.375 M Tris-Cl pH 8.8, 0.1% SDS, 10% 
degassed acrylamide/bis-acrylamide 37.5:1. For polymerization, 5 μL of TEMED and 50 μL of 
ammonium persulphate were added to every 10 mL gel mixture. Stacking denaturing gels 
consisted of 0.125 M Tris-Cl pH 8.8, 0.1% SDS, 10% degassed acrylamide/bis-acrylamide 
37.5:1. For polymerization, 10 μL of TEMED and 50 μL of ammonium persulphate were added 
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to every 10 mL of gel mixture. Afterwards the proteins were transferred at 15 V for 20 min 
from the gel to a 0.45 μm nitrocelulose membrane (Bio-Rad) using a transblot dry Transfer Cell 
(Bio-Rad). The membrane was incubated in blocking buffer (Li-Cor) for 1 hr, rocking at room 
temperature. Afterwards it was incubated with Lex-A antibody (Invitrogen) diluted 1:2,500, 
rocking at 4°C overnight. Next day, the membrane was washed 3 times with PBS+Tween 20 
0.05% (v/v) for 5 min. The membrane was further incubated with the secondary antibody (anti-
rabbit from Li-cor, fluoresces at 800nm) diluted 1:10,000 for 1 hr. The membrane was later 
washed 3 times with PBS + Tween 20 0.1% (v/v) for 5 min. Finally, the membrane was 
visualized with the Li-Cor Imager at 800nm.   
 
4.3. Protocols for manipulation of yeast cells 
 
4.3.1. Yeast mini-preparation 
 Plasmids were isolated according to the protocol described in the yeast minipreparation 
protocol (Geyer and Brent, 2000). A yeast CFU was grown overnight in 2 mL of complete 
supplement mixture (CSM) media (lacking specific amino-acids, such as histidine or 
tryptophan) in a shaking incubator at 30°C. Cells were harvested by centrifugation at 13,000 
rpm for 30 sec. The cell pellet was resuspended in 200 μL of breaking buffer [2% (v/v) Triton 
X-100, 1% (v/v) SDS, 100 mM NaCl, 10 mM Tris-HCl pH 8.0, 1 mM EDTA], followed by the 
addition of 300 μg of glass beads (425-600 nm diameter) and 200 μL of phenol-chloroform-
isoamyl alcohol (25:24:1, v/v/v). Cell walls were disrupted by vortexing the mixture for 2 min. 
Next, the mixture was centrifuged for 5 min at 13,000 rpm, and 50 μL of the aqueous layer 
were stored. Typically 1 μL of the aqueous solution was used for transforming bacterial cells by 
electroporation.  
 
4.3.2. Transformation of yeast frozen competent cells  
 Yeast frozen competent cells were prepared according to the procedure reported by 
Gietz and Schiestl, (2007). A yeast CFU was grown overnight in 25 mL of YPDA 2X at 30°C 
in a shaking incubator. Next day the OD600nm of the culture was determined and 2.5 x 109 cells 
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were added to 500 mL of YPDA 2X. The cell suspension was incubated in a shaking incubator 
at 30°C until an OD600nm of 2 was reached. Then it was centrifuged for 5 min at 4000 rpm, and 
the pellet was resuspended in 250 mL of sterile ddH2O. A second centrifugation step under the 
same conditions was performed, and the pellet was resuspended in 5 ml of sterile ddH2O. A 
third centrifugation step under the same conditions was performed, and the pellet was 
resuspended in 5 ml of sterile frozen competent cell (FCC) solution (5% v/v glycerol, 10% v/v 
DMSO). 50 μL aliquots were dispensed in 1.5 mL microcentrifuge tubes and stored at −80°C, 
temperature at which the cells could be stored for a year with little loss of transformation 
efficiency. DNA transformation consisted of thawing a FCC aliquot at 37°C, following by 
centrifugation at 13,000 rpm for 2 min. The pellet was resuspended in 260 μL PEG 8000 
(50%w/v), 36 μL lithium acetate 1 M, 50 μL single-stranded DNA (2 mg/mL) and 14 μL of 
150-300 ng of plasmid (digested or undigested) and PCR product (if in vivo cloning was 
performed) in water. The mixture was vortexed vigorously and incubated in a thermal block at 
42°C for 45 min, followed by centrifugation at 13,000 rpm for 30 sec. The pellet was 
resuspended in 500 μl of the appropriate synthetic dropout media, and different volumes were 
plated in agar plates containing the appropriate synthetic dropout media, which were incubated 
at 30°C. Transformants were recovered after 4 days.     
 The transformation procedure was also employed to clone DNA fragments into a yeast 
vector by in vivo homologous recombination in yeast (Hua et al., 1997). DNA fragments were 
amplified by PCR, with primers that were 59 bp long, with 39 bp complimentary to the vector 
from the digestion site and 20 bp complimentary to the region to be inserted. Additional 
nucleotides were included if necessary to preserve the appropriate reading frame. The plasmid 
was digested with one or two restriction enzymes, followed by gel purification to remove non-
digested plasmids.  
    
4.3.3. Transformation of yeast cells in 96-well format 
 Transformation of yeast cells in 96-well format was performed according to Gietz and 
Schiestl, (2007). A yeast CFU was dissolved in 10 mL of sterile ddH2O and 100 μL of the cell 
suspension were transferred to each well of a 96-well plate. A replicator (VP 408FH) was used 
to transfer a small amount of liquid from the 96-well plate to a YPDA plate, so the cells could 
grow. The resulting array was incubated overnight at 30°C. Next day, cells from the array were 
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transferred to a 96-well plate containing 100 μL of ddH2O using the replicator. The plate was 
centrifuged at 1,800 rpm for 5 min and the supernatant was removed by using a single shake of 
the plate into a large sink. 50 μL of transformation mix (For 100 reactions: 1.5 mL 1 M lithium 
acetate, 2 mL single-stranded DNA (2 mg/mL), 0.05 μg plasmid/well in 1.5 mL ddH2O) were 
added to each well, shaken at room temperature for 5 min in a shaking incubator. 100 μL PEG 
50% (v/v) were added into each well, and then shaken at room temperature for 5 min in a 
shaking incubator, until the cell suspension became homogenous. The 96-well plate was 
incubated for 1 hr at 42°C, followed by centrifugation at 1,800 rpm for 10 min. The supernatant 
was removed by using a single shake of the plate into a large sink, and the pellet was 
resuspended in 50 μL of ddH2O. 10 μL of the resulting cell suspension were plated in the 
appropriate synthetic drop-out plates using a multichannel pipette, and incubated at 30°C. 
Transformants were recovered after 3 days.   
 
4.3.4. β-Galactosidase Assay 
 A yeast CFU was grown overnight in complete supplement mixture (CSM) media in a 
shaking incubator at 30°C. Next day, the culture was diluted to an OD600nm of 0.15 and the cells 
allowed to grow to an OD600nm of 0.6. 1.2 mL of cells were centrifuged at 13,000 rpm for 5 min, 
and the pellet was resuspended in Buffer Z (sodium phosphate dibasic (Na2HPO4) 0.06 M, 
sodium phosphate (NaH2PO4) 0.04 M, potassium chloride (KCl) 0.01 M, magnesium sulphate 
(MgSO4) 0.01 M). Cells were centrifuged again as in the previous step, followed by the 
addition of: 150 μL Buffer Z (plus β-mercapto-ethanol 0.05 M), 50 μL chloroform, and 20 μL 
SDS 0.1%. The mixture was vortexed, followed by the addition of 700 μL of Buffer Z + ONPG 
(ortho-nitrophenyl-β-galactoside, 1 mg/mL) were added. After 60 to 90 min, the reaction was 
stopped by adding 500 μL of sodium carbonate (Na2CO3 1 M), and then centrifuged for 10 min 
at 13,000 rpm. 200 μL of the mixture were added to a well of 96-well plate and the absorbance 
read in a microplate reader (Spectramax 340PC) at OD420nm. Miller units were calculated 
according to the formula:   
   
)ume)(OD(time)(vol
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600nm
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  Where time is reaction time (min) and volume is reaction volume (mL). 
 
4.4. High-throughput yeast-two-hybrid assay 
 
4.4.1. Cleaning and use of the replicator 
 A replicator (V&P Scientific) was used to make high density arrays of yeast CFUs with 
96, 384 and 1536 spots per array (VP408FH for 96-spot spot format and VP384F for 384-spot 
format). To make 96-well format arrays, the replicator was dipped in 96-well round-bottom 
plates containing 20 to 100 μL of yeast cells, and then pinned into an agar plate. 384-well 
format arrays were made by pinning four times the cells in suspension or colonies in agar 
plates, both in 96-well format. To sterilize the replicator between different arrays, it was first 
dipped in 10% bleach for 30 sec, then dipped in and out in water, and later dipped in 95% 
ethanol for 1 min, then dried with hot air.  
 
4.4.2. Pooling of baits and preys  
 For both the baits and the preys, a yeast CFU was grown overnight in the respective 
synthetic media. Next day, the cells were diluted in the respective synthetic media. After 
measuring the OD600nm for each culture, the number of cells per mL was estimated. For  
encoded baits, an equal amount of cells of every bait was mixed, following the PI-
deconvolution pooling design (Figure 2.6). The mixture was centrifuged for 5 min at 4,000 
rpm, and resuspended in freeze-down solution (65% glycerol, 0.1 M MgSO4, 25mM Tris-Cl pH 
8.0), then stored at –80°C.   
 For yeast-two-hybrid assays in which an interacting pair of preys and baits was diluted, 
we employed the PR domain of RIZ1 fused to the LexA DBD, which interacts with a lariat 
ligand named 6-49, isolated in previous combinatorial library screenings carried out in our lab. 
To perform the dilution of baits and preys in a pool of non-interacting strains, the number of 
cells of the strains was equalized, and then 1:2 or 1:4 dilutions were performed in a 96-well 
plate.    
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4.4.3. Selection of positive interactions with the yeast-two-hybrid assay 
 For both the baits and the preys, a yeast CFU was grown overnight in the respective 
synthetic media. Next day, the cells were diluted in the respective synthetic media. When the 
culture reached an OD600nm of 0.5-0.7, the replicator was employed to transfer the cell 
suspension of the bait or the prey to YPDA plates. After the suspension dried out, a suspension 
of bait or prey was added in the same position of the previously pinned culture. Plates were 
incubated at 30°C. After 2 days, in order to select diploids, the YPDA plates were replicated to 
glucose CSM –HIS –TRP agar plates, keeping a 384-spot format. After another 2 days, the 
plates were replicated to galactose CSM –HIS –TRP –ADE –LEU agar plates to select positive 
yeast-two-hybrid interactions. After another 8 days, the plates were replicated to galactose and 
sucrose CSM –HIS –TRP –ADE –LEU + X-Gal agar plates to select yeast-two-hybrid 
interactions according to growth and blue color formation of the spots.   
 
4.4.4. Estimation of the probability of detecting at least one positive 
interaction with different number of replicates using the yeast-two-hybrid 
assay 
 The probability of detecting at least one positive interaction with different number of 
replicates using the yeast-two-hybrid assay for an interacting bait and prey diluted in pools of 
non-interacting baits and preys, was calculated with binomial coefficients. Experimentally 
obtained values obtained with the yeast-two-hybrid assay indicated the number of positive and 
negative interactions observed in a number of spots. The number of spots tested is the total 
number of spots. The probability of detecting a positive interaction is equal to the ratio of 
positive interactions over the total number of spots. A binomial coefficient was used to 
calculate the total number of combinations of spots for different number of replicates, given by 
the equation:   
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 where n is the total number of spots tested and k is the number of replicates.          
 Second, the number of possible combinations of negative spots were calculated for 
different number of replicates, that is, combinations that would not contain any positive 
interaction; according to the combinatorial formula: 
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 where r is the number of negative spots (in which no interaction was detected), and k is 
the number of replicates.  
 Once these two values were estimated for every replicate (for 2,3,4…n) the number of 
combinations of spots that would show at least one positive hit could was calculated as the 
difference between the total number of combinations of spots and the number of combinatiors 
of negative spots. With these three values, the ratio of the number of combinations containing at 
least one positive spot over the total number of combination of spots is equivalent to the  
probability of detecting at least one positive hit for a certain number of replicates at a given 
dilution of an interacting prey in a pool of non-interacting preys. 
 
4.5. Screening of a combinatorial lariat ligand library for targets pooled 
according to PI-deconvolution  
 
4.5.1. Sorting of combinatorial lariat library into independent tubes 
 The scaffold of the combinatorial library used in our screening was an Ssp-Ssp intein 
engineered to display lariat peptides as a fusion to the B42 AD (Figure 2.3), cloned in the 
pJG4-5 vector, and transformed into the EY93 yeast strain. The library contains seven 
randomized amino-acids in the lariat, as well as two extra EY residues. It was created by Kris 
Barreto and will be referred here after as the R7 library. In order to sort the R7 library into 
individual tubes, 500 μL of the library were dissolved in 100 mL of CSM –TRP +ADE media, 
and incubated for 1 hr at 30°C in a shaking incubator. Viability and cell density were 
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determined under a microscope with a hematocytometer, staining the cells with trypan blue. 
Cells were mixed in a 1:20 ratio with 0.4% trypan blue. The library was diluted in CSM –TRP 
+ADE media to a density of 62.5 viable cells/μL in a final volume of 400 mL. While the cells 
were being stirred with a sterile magnetic stirrer, 16 μL of the cell suspension were dispensed in 
1.2 mL tubes in a 96-well rack containing 400 μL –TRP +ADE, transferring approximately 
1,000 cells per tube. Every cell would ideally contain a different seven amino acid sequence 
displayed as a constrained peptide. The 96-well tube racks were incubated at 30°C in a shaking 
incubator for 2 days. 16 μL of the R7 library cell suspension were plated in CSM –TRP +ADE 
agar plates to determine the number of CFUs.   
 
Pair Pool Baits
1 2 3 + LexA, CC, GEF, SH3
LexA + + + - SH2, SH1, FABD, Y177
CC(aa1-72) + + - + LexA, CC, SH2, SH1
GEF + - + - GEF, SH3, FABD, Y177
SH3 + - - + LexA, GEF, SH2, FABD
SH2 - + + - CC, SH3, SH1, Y177
SH1 - + -
FABD - - +
Y177 - - -
3
Code
Bait 
1
2
 
 
Figure 4.1. Pooling of BCR-ABL domains according to PI-deconvolution.  
 
A set of eight baits, consisting of seven domains of BCR-ABL and a negative control, the DBD 
of LexA, were pooled according to PI-deconvolution. Every bait was pooled into only one pool 
of every pair, in three different pairs. Every bait is assigned a unique code of three bits (nnn).  
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4.5.2. Pooling of BCR-ABL baits according to the PI-deconvolution pooling 
design 
 A yeast CFU containing a bait plasmid was grown overnight in 10 mL CSM –HIS. The 
next day 7 mL of culture were transferred to 25 mL CSM –HIS, and incubated in a shaking 
incubator for 7 hours at 30°C. Afterwards, cell density was determined under a microscope with 
a hematocytometer, diluting the cells 1:20 with 0.4% trypan blue. For every pool, equal 
amounts of bait cells (more than 10 million cells for each bait) were transferred to 250 mL 
CSM –HIS. The pools were incubated at 30°C in a shaking incubator for 3 days, in order to 
obtain high-density cultures.   
 
4.5.3. High-throughput yeast-two-hybrid assay to isolate interacting lariat 
ligands against BCR-ABL baits 
 In order to obtain a high concentration of cells, every R7 96-1.2 mL tube rack was 
centrifuged at 1,800 rpm for 5 min, 150 μL of media was removed from the tube, and the pellet 
was resuspended in the remaining liquid and transferred to a 96-well round bottom plate. The 
same principle was applied for the 4-bait pools, which were diluted 1:10 the day before to a 
final volume of 300 mL CSM −HIS and incubated in a shaking incubator at 30°C. The six pool 
cultures were centrifuged for 10 min at 4,000 rpm, and the pellet was resuspended in 50 mL of 
sterile ddH2O, concentrating the overnight cultures 6-fold. Afterwards, the R7 Ssp-Ssp intein 
library was mated with the 4-bait pools in YPDA agar plates, generating an array of 384 spots, 
each spot containing approximately 1,000 R7 library members (the exact number of CFUs that 
grow on CSM −TRP plates at the time the library was sorted) and 4 baits. Every 96-well plate 
containing the R7 library was pinned using a sterile replicator (VP408FH) in six different 
YPDA agar plates (one for each pool). Every pool culture was pinned using a sterile replicator 
(VP408FH) in one of the previously plated YPDA agar plates with the R7 library. The arrays 
were condensed to 384 spots per plate instead of 96 spots per plate, by pinning the replicator in 
four different positions. The YPDA plates were incubated at 30°C for 2 days. Afterwards the 
YPDA plates were pinned to CSM –HIS –TRP plates and incubated at 30°C for 2 days, in order 
to exclusively allow the growth of diploids. The CSM –HIS –TRP plates were later pinned to 
sucrose and galactose CSM –HIS –TRP –ADE –LEU plates, and incubated at 30°C for 10 days. 
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Afterwards, the sucrose and  galactose CSM –HIS –TRP –ADE –LEU plates were pinned to 
sucrose and galactose CSM –HIS –TRP –ADE –LEU + X-Gal plates, and incubated at 30°C for 
3 days. Spots of the arrays that showed growth and turned blue were determined.   
  
4.6. Screening of a combinatorial protein ligand library with individual baits 
using the yeast-two-hybrid assay 
 A yeast CFU containing a bait plasmid was grown overnight in CSM −HIS media. Next 
day, the cells were diluted in 8 mL of the same media. When the OD600nm was 0.5-0.6, 6.5 mL 
of culture was centrifuged at 4,000 rpm for 5 min. Additionally, 500 μL of R7 Ssp-Ssp intein 
library was diluted in 50 mL of CSM –TRP +ADE. The OD600nm of the R7 library was 
measured and a number of cells, equivalent to one tenth (1/10) of the number of bait cells, were 
transferred to the bait cells pellet. The mixture was centrifuged for 5 min at 4,000 rpm, and the 
pellet was resuspended in a volume of sterile water equivalent to the volume of the cell pellet, 
typically less than 200 μL. The cell suspension was spread uniformly in YPDA agar plates and 
incubated at 30°C overnight. Next day, the cells growing on the surface of the plate were 
collected with a sterile glass slide, and centrifuged for 5 min at 4,000 rpm. The pellet was 
resuspended in glycerol freeze-down solution (65% glycerol, 0.1 M MgSO4, 25mM Tris-Cl pH 
8.0) and stored at –80°C. Next day, an aliquot of the frozen cells was diluted 10-fold serially 
and plated in CSM –TRP and CSM –HIS –TRP, then incubated at 30°C overnight. After two 
days, colonies from the CSM –TRP and CSM –HIS –TRP plates were counted. The mating 
efficiency was calculated as the ratio of colonies from CSM –HIS –TRP plates over the number 
of colonies from the CSM –TRP plates. The number of diploids per μL was estimated from the 
number of colonies from the CSM –TRP plates.  
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4.7. Preparation of media 
 Indications to make synthetic plates and liquid media in the yeast two-hybrid assay are 
described in Geyer and Brent (2000). Synthetic plates and liquid media were prepared in a 1 L 
final volume as described below. 
 
YPDA plates and liquid media: Yeast extract 10 g, Peptone 20 g, Agar (plates only) 20 g, 
H2O 950 ml, Adenine 40 mg. Autoclave YPD media for 20 min at 1.05 kg/cm2 and add 50 mL 
40% (w/v) dextrose. 
 
Dropout plates and liquid media: Yeast nitrogen base without amino acids (BD Biosciences) 
6.7 g, Dropout base (Biol 101 Inc.) x g, Agar (plates only) 20 g. H2O: For dextrose (plates or 
media) 950 ml or galactose/sucrose (plates or media) 925 mL. Where x is equal to the amount 
of the appropriate CSM (complete supplement mixture) dropout base: 0.77 g CSM –TRP; 0.74 
g CSM –HIS; 0.62 g CSM –HIS –LEU –TRP; or 0.61 g CSM –ADE –HIS –LEU –TRP. 
Autoclave media for 20 min at 1.05 kg/cm2 and add either 50 mL of 40% (w/v) dextrose, or 50 
ml of 40% (w/v) galactose and 25 mL of 40% (w/v) sucrose.  
 
X-Gal plates: Yeast nitrogen base without amino acids 6.7 g, Dropout base x, Agar 20 g. H2O: 
(glucose plates or media) 850 mL or (galactose/saccharose plates or media) 825 mL. Where x is 
equal to the amount of the appropriate CSM dropout base: 0.74 g CSM –HIS, or 0.62 g CSM –
HIS –LEU –TRP, 0.61 g CSM –ADE –HIS –LEU –TRP. Autoclave media for 20 min at 1.05 
kg/cm2 and add either 50 ml of 40% (w/v) glucose, or 50 ml of 40% (w/v) galactose and 25 mL 
of 40% (w/v) sucrose. Cool media to 55°C and add 10X BU salts (see below). Add 4 mL of 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal; 20 mg/mL dissolved in dimethyl 
formamide).  
 
BU Salts: Na2HPO4 · 7H2O 70 g, NaH2PO4 30 g, H2O 900 mL. Adjust 10X BU salts to pH 7.0 
and autoclave BU salts for 20 min at 1.05 kg/cm2. 
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5. RESULTS 
 
5.1. Cloning of domains of BCR-ABL into a yeast-two-hybrid expression 
vector 
 BCR-ABL is an oncogene that results as a consequence of the fusion of ABL and BCR 
through a chromosomal rearrangement. The tyrosine kinase of BCR-ABL+ becomes 
constitutively active and BCR brings new regulatory domains/motifs to ABL (Ren, 2005). 
BCR-ABL is responsible for most cases of chronic myelogenous leukemia.  
 The most important domains for BCR-ABL oncogenesis were selected to be screened 
against a combinatorial protein ligand library using the PI-deconvolution pooling design. 
Domains that affect the overall structure of ABL kinase (CC, SH3, SH2), play a role in 
signaling pathways (Tyrosine Y177) or possess specific functions (GEF, FABD, SH1 tyrosine 
kinase) were cloned. The position of each domain in BCR-ABL was based on reported data of 
structural studies and mutation analysis of the activity of the different domains (Figure 5.1a). 
The seven chosen domains of BCR-ABL were cloned as a fusion to LexA DNA-binding 
domain (DBD) in a yeast-two hybrid expression vector (pEG202). Domains were amplified by 
PCR from a plasmid containing human BCR-ABLp210 and cloned in vivo by homologous 
recombination in yeast (Hua et al., 1997). None of the constructs were found to auto-activate 
the yeast-two-hybrid reporters and their sequences were verified. The FABD domain contained 
a mutation of Threonine to Serine in amino-acid position 1,084 of ABL that is not conserved 
among species distantly related phylogenetically. Furthermore, the expression of the fused 
domains was confirmed by immunoblot using a LexA antibody (Figure 5.1b). The observed 
molecular weight of all domains corresponds to their expected molecular weight, suggesting the 
fusion proteins are expressed in-frame and with the expected molecular weight. 
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a) 
 
 
Protein Domain 
Position in 
BCR or 
ABL* 
Size of LexA-
domain fusion 
(KDa) 
Reference 
Coiled-coil (CC) 1-72 31.2 Zhao et al., 2002 
Y177 171-182 24.3 Puil et al., 1994 
BC
R
 
Guanidine-exchange 
factor (GEF) 501-589 43.8
Chuang et al., 
1995 
Src-Homology 3 
(SH3) 65-119 28.7
Gosser et al., 
1995 
Src-Homology 2 
(SH2) 120-220 34.1
Overduin et al., 
1992 
Src-Homology 1, 
Tyrosine kinase 
(SH1) 
229-515 55.8 Schindler et al., 2000 
A
BL
 
is
of
or
m
 1
b 
F-Actin binding 
domain (FABD) 1026-1149 36.2
Hantschel et al., 
2005 
*NCBI accession numbers. BCR: gi29241, ABL: gi62362411.  
 
b) 
 
Figure 5.1. Expression of LexA- fusion BCR-ABL domains.  
 
a) List of domains of BCR-ABL that were cloned as a LexA-domain fusion into a yeast-two-
hybrid expression vector. Position within the protein sequence of BCR or ABL is shown, as 
well as the expected molecular weight of the fusion proteins. b) Western Blot  with an anti-
LexA antibody of yeast lysates from cells expressing LexA-domain fusions. The molecular 
weight of the fusion proteins is shown in panel a). The molecular weight of a protein ladder is 
shown to the left of the blot. All the domains showed the expected molecular weight. 
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5.2. Detection limits of the yeast-two-hybrid assay 
 Two issues must be addressed in order to screen protein ligand combinatorial libraries 
using PI-deconvolution. The first issue involves pooling the baits according to PI-
deconvolution; it pre-determines the number of baits to be pooled following the exponential 2n, 
(i.e. 8, 16, 32, 64, 128, etc.). The second component is a matrix-based screening of the protein 
ligand combinatorial library. The large number of members a library of this kind contains, 
around 107 transformants, makes it necessary to pool library members for every ‘spot’ of the 
array (Figure 2.4). Otherwise, thousands of 96- or 384-spot arrays would be needed to perform 
one single screening. Therefore, the number of cells per spot for every array should be 
condensed (or pooled) at least 100-fold, so fewer plates are required to be assayed. The ideal 
scenario would be to sort the library in an array in which every spot would contain between 100 
and 2,000 members. This way, the library could be stored in a reasonable number of 384-spot 
arrays. The detection of protein-protein interactions using the yeast-two-hybrid assay decreases 
when the interacting bait and prey are diluted more than 100-fold in a pool of non-interacting 
baits or preys. We needed to determine how diluting an interacting prey in a pool of non-
interacting preys would affect the performance of the yeast-two-hybrid assay. Note that in study 
the baits would be pooled according to PI-deconvolution, whereas the library members would 
not be pooled according to any pooling design. They would be pooled randomly using a certain 
density of preys per spot on the array.  
 To establish the dilution threshold of the yeast two-hybrid assay we used a previously 
known interacting prey and bait. More specifically, a lariat ligand referred to as 6-49 (prey) that 
interacts with the PR domain of RIZ1 (bait). It was isolated previously in the Geyer lab from a 
combinatorial lariat ligand library screening using the yeast-two-hybrid assay. We determined 
the sensitivity of the yeast-two-hybrid assay by diluting the prey 6-49 and the RIZ1 bait in a 
pool of strains containing non interacting preys (pJG4-5) and baits (pEG202-SH1) (Figure 
5.2a). A yeast-two-hybrid assay was performed to identify the dilutions where the interactions 
are no longer detectable. The results show how diluting the interacting baits or preys affects the 
number of positive hits detected in a negative way (Figure 5.2b). Nonetheless, the assay does 
detect the interaction of RIZ1 with 6-49 when the 6-49 prey is diluted between 500- and 1,000-
fold and the RIZ1 bait diluted between four- and eight-fold per spot. The data confirms that the 
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yeast-two-hybrid assay loses sensitivity when the interacting bait and strain are diluted in a pool 
of non-interacting baits and preys.  
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Figure 5.2. Sensitivity of the yeast-two-hybrid assay.  
 
a) A prey strain containing a lariat peptide (6-49) that interacts with RIZ1 was diluted 2-fold in 
an equivalent number of non-interacting strains (prey harbouring the pJG4-5 vector, does not 
express a lariat peptide). In a similar fashion, a RIZ1-expressing bait was diluted 2-fold in a bait 
expressing SH1, which does not interact with the lariat peptide 6-49. The number of positives 
hits detected decrease as you move diagonally in the array (arrow). b) Percentage of positive 
hits detected for a serially diluted interacting prey in a pool of non-interactors. Interacting bait 
was diluted 1:4 in a pool of non-interactors. Experimental values from experiment shown in a). 
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5.3. Probability of detecting at least one positive hit 
 We have shown that a yeast-two-hybrid assay with an interacting prey and bait diluted 
in a pool of non-interacting strains can be performed. The possibility to also pool a library as 
hundreds of library members per spot enforces our aim to develop a high-throughput 
combinatorial screening of lariat ligand libraries. In order to unambiguously deconvolute a code 
to one target, the value of all the bits from the code must be determined. In other words, an 
interaction must be detected for every pair in only one of two pools. If the interaction of a 
diluted bait and prey is tested many times, or several replicates are tested, the probability of 
detecting it increases. We wanted to determine how many times (or replicates) an interaction 
should be tested in order to detect at least one positive interaction. 
 For the experimental data shown on Figure 5.2b, the proportion of positive hits is equal 
to the probability of detecting an interaction for only one spot (replicate). For example, for the 
1:024 dilution a proportion of 0.659 was observed, because fifty-eight spots were positive out 
of eighty-eight (Figure 5.3a). If the experiment is repeated again once for that dilution, it can 
be seen as taking only one spot of the eighty-eight spots tested. If various spots are tested again, 
it can be seen as picking certain combinations of those eighty-eight spots, depending on the 
number of spots tested (replicates). If three replicates were tested, it can be seen as taking any 
three spots from the 88 spots originally tested. Whereas some combinations will contain 
positive hits and some will contain only negative hits, in our case we want to detect spots that 
contain at least one positive interaction. To do so, we used a binomial coefficient to determine 
all the possible combinations of spots for those three replicates. Afterwards, we determined all 
the possible combinations of spots that would contain only negative interactions, also using a 
binomial coefficient. When the total number of negative spots is subtracted from the total 
number of spots the result is all the possible combinations of spots that contain at least one 
positive hit. This value was divided by the total number of spots to estimate the proportion of 
positive hits, the same as the probability of detecting at least one positive hit per spot for an 
interacting bait and prey for replicates of an interaction. (Figure 5.3a). It can be seen that after 
eight replicates all the dilutions tested reach a probability equal to one, which means that 
having eight replicates for one spot will ensure detecting at least one positive hit, a condition 
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necessary to apply the PI-deconvolution pooling design to the screening of combinatorial 
libraries (Figure 5.3b).  
  
a) 
  
Number of 
replicates
Total 
combinations 
of spots
Combinations 
of negative 
spots
Combinations 
of at least one 
positive spot
Probability of 
detecting at least 
one positive spot
1 88 30 58
2 3828 435 3393 0.886
3 109736 4060 105676 0.963
4 2331890 27405 2304485 0.988
5 39175752 142506 39033246 0.996
6 541931236 593775 541337461 0.999
7 6348337336 2035800 6346301536 1.000
8 64276915527 5852925 64271062602 1.000
0.659
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Figure 5.3. Probability of detecting at least one positive hit for different dilutions of an 
interacting prey in a pool of non-interacting preys with different replicates of a spot.  
 
a) Example of the combinatorial algorithm, values obtained when a yeast-two-hybrid assay 
performed with the interacting bait (RIZ1) was diluted 1:4 and the interacting  prey (6-49) was 
diluted 1:1024. b) The number of replicates for every spot needed to detect at least one positive 
hit for different dilutions of an interacting prey in a pool of non-interacting preys and an 
interacting bait diluted 1:4. Values calculated using a combinatorial formula. 
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 We wanted to determine the optimal dilution of preys to perform our screening and the 
number of replicates it required. We aimed to screen one million library members. In a 
screening, there is a strict relationship between the dilution of preys, the number of replicates, 
and the number of arrays. The fewer arrays needed to contain one library, the more efficient the 
screening will be in terms of cost and time (Figure 5.4). We chose to pool about 1,000 cells per 
spot. In this dilution, detecting at least one (+) hit with a probability higher than 0.98 per spot 
requires testing at least four replicates. Following these parameters, one million library 
members would be contained in sixty-one plates (arrays). We could also have chosen the 
1:2,048 dilution, however this choice would imply the need for five replicates to detect a 
positive hit with a probability of 0.98, thus the construction of the arrays would be difficult 
because they must be constructed in series of two or four. For example, one 96-well array 
containing 96 different samples can be converted into four replicates by condensing it 4 times 
into a 384-spot array. Making four replicates per spot is easier than constructing other number 
of replicates, because one 384-spot array is made from condensing four 96-spot plates using a 
pin tool. This way one 96-well plate with 1,000 library strains per well has to be replicated four 
times into an array plate. Overall, the conditions for the screening of a combinatorial protein 
ligand library against a pool of four baits had been established: Approximately 1,000 cells from 
the library would be used per spot, and every spot would contain four replicates. 
 
5.4. High-throughput yeast-two-hybrid assay with an interacting bait pooled 
according to PI-deconvolution  
 Once the optimal parameters for the screening a combinatorial protein ligand library 
using four pooled baits (from the 1:4 dilution) were established, we performed a small-scale 
mock screening with lariat ligand 6-49 and RIZ1. In this case, RIZ1 was pooled according to 
the PI-deconvolution pooling design for eight baits, which determined that the interacting bait 
should be diluted 4-fold in a pool of non-interacting baits, instead of diluting 2-fold serially as 
in previous experiments. Positive hits are found in the pools in which RIZ1 is present, 
unambiguously deconvoluting to the code ‘− + −’, which corresponds to RIZ1 (Figure 5.5). 
Dilution of the preys to more than 1:64 decreases the number of positive hits detected. Almost 
no interactions can be detected when diluting the preys more than 1:2,048.  
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Figure 5.4. Number of plates required to screen one million members of a combinatorial 
library. 
 
The number of plates required for every step of the screening of pools of four baits against one 
million members of a combinatorial lariat ligand library was calculated based on the number of 
replicates needed to detect at least one positive interaction with a probability of 0.98. A step is 
defined as the media in which the cells will be replicated, for example from glucose CSM –HIS 
–TRP to galactose and sucrose CSM –HIS –TRP –ADE –LEU  plates. 
 
 Nonetheless, we observed some positive interactions in spots in pools where the 
interacting bait (RIZ1) was not present. This is likely due to appearance of false positives. 
However, as the 6-49 lariat ligand is diluted more than 1:128, positive hits are not detected 
where the bait is not present (Figure 5.6). This suggests that pooling several lariat ligands in 
one spot contributes to the elimination of false positives. The results confirm that several baits 
can be effectively screened with combinatorial protein ligand libraries using the PI-
deconvolution pooling design. The parameters we have established are appropriate to ensure the 
detection of all the interactions between an interacting bait and prey when they are diluted in a 
pool of non-interacting baits and preys.  
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a)     b)   
0 1 2
LexA + + +
GFP + + -
JH1 (JAK2) + - +
GST + - -
SH2 (ABL) - - +
SH1(ABL) - - -
CDK2 - + +
RIZ1 - + -
PairBait
 
                                                                                                               
Figure 5.5. A mock screening of a known interaction between RIZ1 and peptide lariat 6-
49 pooled with non-interacting baits and preys using PI-deconvolution.  
 
(a) Eight baits were pooled-encoded into 3 pairs of (+) and (−) according to the PI-
deconvolution pooling design. RIZ1 was encoded as ‘− + −’. Other proteins expressed as fusion 
to the LexA DNA-binding domain included green fluorescent protein (GFP), JH1 domain of 
janus kinase 2 (JAK2), glutathione-S-transferase (GST) and cyclin-dependent kinase 2 (CDK2) 
(b) A strain expressing a lariat peptide (6-49) that interacts with RIZ1, was serially diluted 4-
fold and 2-fold in a pool containing a non-interacting strain (pJG4-5). The pools that grew in 
auxotrophic media are encoded as ‘− + −’, which deconvolutes to RIZ1. Detection of (+) hits 
decreases as the strain expressing 6-49 is diluted. Each spot of the array was tested four times.  
 
5.5. PI-deconvolution screening of a lariat ligand combinatorial library 
 We screened a lariat ligand combinatorial library against eight baits pooled into six 
pools according to PI-deconvolution with the yeast-two-hybrid assay (Figure 4.1). Baits 
screened included domains of BCR-ABL (CC, Y177, GEF, SH3, SH2, SH1, and FABD) and 
the DNA-binding domain of LexA. The DBD of LexA was used as a negative control to 
identify lariat ligands that interact against the DNA-binding domain of LexA, not with BCR-
ABL domains. The scaffold of the lariat ligand combinatorial library was an engineered Ssp-
Ssp intein that displays cyclic peptides as lariats. It contained seven randomized positions in 
addition the fixed amino-acids EY in the cyclic peptide formed by the intein (Figure 2.3).  
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Figure 5.6. Diluting an interacting lariat ligand in a pool of non-interacting preys 
eliminates the false positives that arise during a high-throughput yeast-two-hybrid assay 
with baits pooled according to PI-deconvolution.  
 
Proportion of (+) hits from a mock deconvolution combinatorial library screening for PI-
encoded pools (4 baits per pool) with different dilutions of the interacting prey. A yeast-two-
hybrid high-throughput assay was performed with 6 pools, each containing 4 baits. Baits were 
pooled according to PI-deconvolution. Pools consisted of three pairs, each containing a ‘+’ pool 
and a ‘– ‘ pool, labelled 1–, 1+, 2–, 2+, 3–, 3+.  RIZ1 was only present in the pools 1–, 2+ and 
3–. It interacts with the lariat ligand 6-49, diluted serially in a pool of non-interacting preys. 
Positive interactions should be only observed in the pools where RIZ1 was included, although 
some positive interactions were detected in the pools were RIZ1 was not present, due to the 
intrinsic noise of the assay. However, as the 6-49 lariat ligand is diluted, the unexpected 
interactions are no longer detected.  
 
 The screening process is outlined in Figure 5.7. Approximately one million members of 
the combinatorial library were screened. The library was sorted in 1,536 spots from sixteen 96-
tube racks, where every spot of the array contained approximately 750 cells per spot. Every 
spot was plated four times, thus four replicates of every spot were screened. The sorted library 
was mated with every pool (6 pools in total), and diploids that carried the bait and the prey 
plasmids were selected. The diploid colonies were plated to agar plates containing galactose 
and sucrose CSM –HIS –TRP –ADE –LEU, where only colonies with positive interactions 
(hits) are able to form colonies. Afterwards, the arrays were plated to plates containing 
galactose and sucrose CSM –HIS –TRP –ADE –LEU +X-Gal, where positive interactions were 
selected by appearance of blue colonies.    
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Figure 5.7. Screening of a combinatorial library using PI-deconvolution.  
 
A lariat ligand combinatorial library is mated to six pools that contain eight baits pooled 
following PI-deconvolution. Positive interactions (hits) are selected by growth in plates lacking 
leucine and adenine, and later in plates containing X-Gal, in which the positive interactions turn 
blue. The results from the –ADE –LEU and X-Gal selection plates are combined and from there 
those spots that show PI-deconvolution are selected. Positive hits from those spots are plated 
into sucrose and  galactose (gal) CSM –HIS –TRP –ADE –LEU +X-Gal and glucose (glu) 
CSM –HIS –TRP –ADE –LEU +X-Gal to eliminate false positives; colonies plated in Glu 
CSM –HIS –TRP –ADE –LEU +X-Gal will not grow if the activation of the reporter genes 
depends on the interaction of the bait and the prey. Furthermore, hits grown in sucrose and 
galactose CSM –HIS –TRP –ADE –LEU +X-Gal should grow and turn blue again. The lariat 
plasmids are isolated and retransformed into an empty yeast strain, followed by a second yeast-
two-hybrid assay to confirm the previously detected interactions. Finally, the DNA sequence of 
the lariat encoding region is obtained from the confirmed positive interactions.     
 
 Positive interactions from both galactose and sucrose CSM –HIS –TRP –ADE –LEU 
plates with and without X-Gal were determined. Bear in mind that one spot could present up to 
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four positive hits, because every spot was tested four times (four replicates). In order to analyze 
the data, the positive hits from all the spots (four hits per spot) were grouped in either one of 
three categories (Figure 5.8a): Single hits, partially deconvoluted hits, and deconvoluted hits. 
Single hits appeared in only one out of the six pools. Partially deconvoluted hits appeared in 
only two out of the three pairs (i.e. following the code ‘− + ?’, or ‘+ + ?’, ‘?’ represents no 
interaction detected). Deconvoluted hits appeared in all three pairs and only one pool of each 
pair (either in the – or + pair, but not both), hence showing a deconvoluted pattern (i.e. + – +, + 
+ –) that can be uniquely associated with one of the eight baits included in the pools. A fourth 
category, named not deconvoluted, was assigned to positive interactions in spots in more than 
one pool of the same pair; these are potential false positives. A total of 1432 positive 
interactions (positive hits) were found in 775 spots. The majority of positive hits were present 
as single hits, and a minor proportion (53 out of 775), were deconvoluted (Figure 5.8b). 
Deconvoluted positive hits are likely true interactors because they show a reproducible and 
consistent deconvoluted pattern (Jin et al., 2006).  
 
a) 
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b) 
 
Deconvoluted Partially deconvoluted
Single 
hits
Not 
deconvoluted Total
Spots 53 127 559 36 775
(+) Hits 321 311 631 169 1432  
 
Figure 5.8. PI-Deconvolution categories.  
 
Criteria developed to evaluate the outcome of the screening of a combinatorial lariat ligand 
library using PI-deconvolution. a) Deconvolution categories. A spot is labelled deconvoluted 
after presenting at least one positive hit in only one pool (+ or – ) or every pair (1/2/3); this way 
the spot can be assigned a ‘code’, in the example being ‘+ + –’, which decoded to the coiled-
coil domain. If one of the pairs lacks one positive hit, it is considered partially deconvoluted. In 
this case, deconvolution can be applied and could be decoded to two baits (out of eight). A third 
case, if a spot presents a positive hit in only one pool out of the six pools, it is considered single 
hit, which can not be assigned any code, and most probably represent a false positive. b) 
Summary of deconvolution categories of a PI-deconvolution screening of a combinatorial 
protein ligand library. The number of spots for each category and the number of hits 
(replicates) that appeared in every spot are shown. Every spot could present up to four hits. A 
fourth category consists of not deconvoluted spots, in which a positive hit was observed in both 
pools of one pair, in the ‘+’ and the ‘–’ pool.  
 
5.6. Deconvoluted spots showed high deconvolution scores 
 Another parameter that we developed to evaluate the outcome of the screening of 
protein ligand combinatorial library is the deconvolution score. For the screening of a 
combinatorial lariat ligand library, we reasoned that for a deconvoluted spot, the more hits that 
were detected, the more likely they would be a true interaction. In order to verify this 
hypothesis, every spot that showed positive interactions was assigned a deconvolution score. 
This score reveals the number of positive hits detected per spot, since every spot has four 
replicates. For the conditions used in our screening, the optimal score would be twelve, since 
for one spot, which is represented in three pools, there would be four positive hits per pool 
(from the four replicates). Therefore, the deconvolution score would be twelve. Analyzing the 
deconvolution score of all the spots could provide more information about the positive hits 
isolated in the screening rather than focusing on the deconvolution pattern alone (Figure 5.9). 
Single hits comprised the majority of the hits detected in the screening. The vast majority were 
present as isolated single hits, with very low deconvolution scores. The same behaviour was 
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observed for the partially deconvoluted spots, in which the vast majority of the spots showed an 
interaction only in one or two of the replicates. For deconvoluted spots a different trend is 
observed, since spots with high deconvolution scores were observed. 
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Figure 5.9. Distribution of the deconvolution score for spots that showed positive 
interactions after a screening of a combinatorial lariat ligand library for different 
deconvolution categories. 
 
Deconvolution score depends on the deconvolution category. For example, for single hits, the 
score ranges from 1 to 4 since for one spot there are only 4 replicates. For partially 
deconvoluted hits, the score ranges from 2-8, since there are two spots and 4 replicates per spot; 
also there must be at least 2 hits (one hit in every pool) for the spot to be classified as partially 
deconvoluted. a) Distribution for single hits. b) Distribution for partially deconvoluted hits. c) 
Distribution for deconvoluted hits.    
5.7. Confirmation of the interaction of deconvoluted positive spots with their 
predicted target  
 Due to the appearance of false positives in yeast-two-hybrid screenings, it is necessary 
to confirm detected interactions, a process that is both time-consuming and labour-intensive. To 
confirm a yeast-two-hybrid interaction, the prey plasmid must be isolated from the colonies 
(diploids) that showed a positive interaction, inserted again in a prey yeast strain, followed by a 
second yeast-two-hybrid assay with the bait it interacted with in the screening. Elimination of 
false positives is one of the reasons that lead us to adapt the PI-deconvolution pooling design to 
the screening of combinatorial protein ligand libraries using the yeast-two-hybrid assay. 
Therefore, we tested detected interactions from the screening to evaluate the usefulness of the 
approach and verify that positive hits isolated were indeed true positives. A 96-spot array was 
created with randomly selected colonies from deconvoluted spots (arrayed in duplicate). Spots 
that were not be deconvoluted were also included in the array, the case of 6[4H], 10[10D], 
12[7H]; or partially deconvoluted, such as 6[8F] and 7[10D] (Table 5.1). Positive and negative 
controls were included as well to fill all 96-spots of the array (not shown). The 96-spot format 
facilitated handling of the samples with a 96-pin replicator or a multichannel pipette.  
 Galactose-dependence yeast-two-hybrid expression of the reporters was tested with the 
spots from the array. The expression of the lariat ligands is only activated by galactose and 
inhibited by glucose; therefore colonies that grow on plates that contain glucose are not 
expected to be true yeast-two-hybrid interactors. The array was replicated to galactose and 
sucrose CSM –HIS –TRP –ADE –LEU plates, and glucose CSM –HIS –TRP –ADE –LEU 
plates. Only spots that grew on galactose and sucrose CSM –HIS –TRP –ADE –LEU plates but 
not in glucose CSM –HIS –TRP –ADE –LEU plates were considered yeast-two-hybrid 
positives, therefore the interaction of the lariat ligand with its target was expected to be 
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reproduced. Colonies from spots that grew on glucose CSM –HIS –TRP –ADE –LEU plates or 
failed to grow in galactose CSM –HIS –TRP –ADE –LEU plates were not expected to be 
reproducible yeast-two-hybrid positive hits. After the confirmation of galactose-dependent 
expression of yeast-two hybrid reporters, the interactions of the 96 spots of the array were 
further confirmed by isolating the prey plasmid and reinserting it in a prey strain, followed by a 
second yeast-two-hybrid assay. Only the interactions of colonies from thirty-one spots that 
passed the galactose-dependency test were positive for this second yeast-two-hybrid assay 
(Table 5.1). The interactions of the spots that showed gal-dependence were confirmed. These 
spots were either deconvoluted or non deconvoluted positive spots (Table 5.1). Spots were 
found to interact with the GEF domain of BCR, and SH3, SH1, and FABD domains of ABL. In 
particular,  6[4H] and 7[10D] spots interacted with the FABD domain of ABL. 1[2E] and 
4[11B] interacted with the SH3 domain of ABL and 11[9A] with the SH1 domain of ABL. 
Remaining spots interacted with the GEF domain of BCR. No confirmed positive hits were 
found to interact with other BCR-ABL domains present in the pools, although some were 
predicted to interact with the coiled-coil domain (3[12B]), Y177 (2[12H]) of BCR, or LexA 
(13[1C]. We did not isolate lariat ligands that interact with LexA, although other screenings 
performed in our laboratory have identified lariat ligands that interact with this domain. It is 
possible that the fraction of the library screened was not diverse enough to contain a LexA 
lariat ligand. 
 Nonetheless, we found an association between the deconvolution score of the 
deconvoluted spots and whether the interaction of these hits with their targets would be re-
confirmed (Figure 5.10). Deconvoluted spots whose interactions with their target were not 
confirmed showed low deconvolution scores, whereas the opposite occurred for deconvoluted 
spots with high deconvoluted scores: All their interactions with their targets were confirmed. 
All interactions from deconvoluted spots with deconvolution scores higher than eight were 
confirmed, and only two interactions were not detected for deconvoluted spots with 
deconvolution scores higher than six. Overall, the deconvolution score can be used as a useful 
parameter to evaluate whether the interactions found in deconvoluted spots will be confirmed or 
not. Considering only deconvoluted spots with high deconvolution scores (such as eight) could 
eliminate completely the need to confirm positive interactions observed after a screening of 
protein ligand combinatorial libraries using the yeast-two-hybrid system.   
 67
  
0%
20%
40%
60%
80%
100%
120%
3 4 5 6 7 8 9 10 11 12
Deconvolution score
P
er
ce
nt
ag
e 
of
 c
on
fir
m
ed
 s
po
ts
 
 
Figure 5.10. Distribution of the deconvolution score for deconvoluted spots whose 
interactions were subjected to reconfirmation 
 
The deconvolution score was calculated for the deconvoluted spots from the array that was re-
confirmed. For confirmed spots the interaction with their predicted bait was observed when a 
yeast-two-hybrid assay was repeated with retransformed prey plasmid. The deconvolution score 
ranges from three to eight because there must be at least three. Only deconvoluted spots were 
considered, spots that were confirmed but were not deconvoluted or partially deconvoluted 
were not included. 
 
5.8. Sequencing of the lariat region of the confirmed deconvoluted positive 
hits 
 One advantage of performing combinatorial screenings with genetic systems rather than 
chemical-based systems is the ability to determine the identity of the interacting agents by 
amplifying their plasmids and obtaining their DNA sequence. Figure 5.11 shows predicted 
amino-acid sequences of the lariat ligand coding region of reconfirmed positive hits (Table 
5.1), since they are likely true interactors as suggested by the yeast-two-hybrid assay. All the 
sequences obtained corresponded to the Ssp-Ssp lariat intein scaffold (Figure 2.3), in which 
seven amino-acids were randomized for the construction of the combinatorial library. We also 
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show the regions adjacent to the variable region of this scaffold (on the N-terminus –AS-, 
followed by –CLS- on the C-terminus and the –EY- residues, which also constitutes the lariat. 
Most of the sequences contained seven residues in their variable region as expected (the only 
exception was 15[8H], which presents a stop codon in the 7th residue). Some of the isolated hits 
that contain the –ALS sequence instead of –CLS do form an inactive version of the intein, 
instead of the full cyclic peptide displayed by the lariat (Figure 2.3); however, these hits 
interacted with their targets in the yeast-two-hybrid assay. Altogether, the determination of the 
sequence of the isolated hits offers new perspectives to evaluate whether these hits have 
biological or inhibitory activity. It also allows the chemical synthesis of cyclic peptides with the 
nine amino-acid sequence, as well as mutational analysis.  
 
a)             b) 
 Spot pre-7X Variable region post-7X
Predicted 
Target
4 [11B] AS PHSVFGQ EY-CLS SH3
11 [9A] AS SGGCWAQ EY-ALS SH1
1 [11C] AS MIPWCTY EY-CLS GEF
1 [9F] AS LMWWMPH EY-CLS GEF
10 [1A] AS DWWRGRR EY-CLS GEF
12 [7H] AS LRPGARR EY-ALS GEF
13 [1G] AS TLWFLHG EY-ALS GEF
13 [6F] AP KMWFFES EY-CLS GEF
14 [10E] AS VLWFFSG EY-CLS GEF
14 [5A] AS LLWFWPG EY-CLS GEF
14 [5G] AS YNRGARR EY-CLS GEF
15 [11F] AS YSRGGRR EY-CLS GEF
15 [8H] AS EGHPCD. EY-CLS GEF
15 [9E] AS EFWQFSH EY-CLS GEF
16 [7F] AS GFWWLTG EY-CLS GEF
16 [8A] AS FVCGARR EY-ALS GEF
2 [6F] AS RWFAVFN EY-CLS GEF
3 [2B] AS LVPGARR EY-ALS GEF
3 [8F] AS YMWWWSG EY-CLS GEF
4 [2H] AS WVRNSRR EY-ALS GEF
5 [12H] AS QLWFWPR EY-CLS GEF
6 [3E] AS TLWFLHG EY-ALS GEF
6 [5A] AS RLWMLTA EY-CLS GEF
7 [5A] AS RLWLFMR VY-CLS GEF
9 [5G] AS YMWWWSG EY-CLS GEF
6 [4H] AS GLSWPAE EY-CLS FABD
7 [10D] AS GWVSQKG EY-ALS FABD
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11. Predicted amino acid sequence of the variable region of the confirmed lariat 
ligands. 
 
a) The DNA sequence of the lariat ligands from spots whose interactions were confirmed is 
shown, divided in three segments. The pre-7X and post-7X refers to the residues adjacent to the 
variable region of the lariat ligand, which is contained in the Ssp-Ssp intein scaffold (see 
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Figure 2.3). The variable region refers to the region of the Ssp-Ssp intein that forms the lariat 
cyclic peptide, along with two fixed EY residues. The variable region was randomized for all 
twenty standard amino acids. It is also shown the BCR-ABL domain the lariat ligands 
interacted with according to the yeast-two-hybrid assay. b) Yeast-two-hybrid assay showing the 
interaction of the confirmed spots that were sequenced with their target. Every spot showed an 
interaction with one domain of BCR-ABL exclusively. Colonies showed growth in sucrose and 
galactose CSM –HIS –TRP –ADE –LEU plates. 
 
 We reasoned that the isolated lariat ligands should share structural similarities that 
would be revealed by an analysis of their amino-acid sequence through the generation of a 
phylogenetic tree. Although the lariats are not evolutionary related, the generation of a 
phylogenetic tree provided a good way to group or cluster the most similar lariats. A tree was 
generated using the software MegAlign (DNAstar Inc., 1997) using default conditions. The 
amino-acid sequences used for the alignment were variants of the AHAS-X7EY-CLSFG 
sequence, where X7 represents the variable region of the lariat ligand. Remarkably, the 
sequences of the isolated lariat ligands are grouped into well defined clusters (Figure 5.12). 
Lariat ligands  (4[11B], 6[4H], 7[10D] and 11[9A]) that showed interaction with a domain 
different from the GEF domain clustered independently from other sequences and are not 
similar to the rest of the sequences as well. On the other hand, the GEF lariat ligands grouped 
into well defined clusters, showing specific consensus sequences. One of these clusters is 
defined by the XXXGARR consensus (where X represents any amino-acid) derived from the 
five lariat ligands 12[7H], 3[2B], 16[8A], 14[5G] and 15[11F]. Another cluster of five 
sequences is defined by the consensus X-XNP-W-W/F-XNP-X-G (where X represents any 
amino-acid and XNP represents a non-polar amino-acid), derived from the lariat ligands 
13[1G]/6[3E], 16[7F], 3[8F]/9[5G], 14[5A], 5[12H]. The remaining lariat ligands did not group 
into a specific cluster, as is the case for 13[6F], 7[5A]/9[12E], 1[11C] and 15[8H]. Overall, the 
well defined clustering of some of the isolated lariat ligands suggests they are true interactors, 
not artifacts of the yeast-two-hybrid assay. If they were not true interactors, they would not 
show a defined phylogenetic pattern, since there would not be a structural consensus underlying 
their sequences. 
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Table 5.1. Confirmation of interactions from deconvoluted, partially and not 
deconvoluted spots.  
 
1 - 1+ 2 - 2+ 3 - 3+
1[2E] 1 3 1 5 + +
1[3F] 2 3 1 5 + +
1[9F] 1 3 1 5 + +
1[11C] 4 4 4 12 + +
2[5F] 1 1 1 3 - -
2[6F] 1 2 1 4 + +
2[12H] 1 2 1 4 - -
3[2B] 4 3 2 9 + +
3[8F] 2 2 1 5 + +
3[12B] 2 2 1 5 - -
4[2A] 1 1 1 3 - -
4[2H] 4 1 3 7 + +
4[11B] 3 2 3 8 + +
5[12H] 4 4 2 10 + +
6[2C] 1 1 1 3 - -
6[3E] 4 3 3 10 + +
6[4H] 3 1 3 1 ND + +
6[5A] 4 1 1 6 + +
6[8F] 1 1 PD - -
7[5A] 3 2 3 8 + +
7[10D] 1 2 PD + +
9[5G] 4 4 3 11 + +
9[12E] 1 2 1 3 - -
9[12H] 1 1 1 3 - -
10[1A] 3 2 1 6 + +
10[1B] 1 2 2 5 - -
10[10D] 1 1 1 1 ND - -
11[9A] 1 3 2 6 + +
12[3C] 1 1 1 3 - -
12[7H] 1 1 3 1 ND + +
12[12H] 4 1 2 7 - -
13[1C] 1 1 1 3 - -
13[1G] 3 4 4 11 + +
13[4H] 1 3 2 6 - -
13[6F] 4 4 4 12 + +
13[9B] 3 1 1 5 + +
13[12B] 2 2 2 6 + +
14[5A] 4 4 4 12 + +
14[5G] 2 1 1 4 + +
14[10E] 1 1 2 4 + +
14[11C] 2 1 1 4 - -
15[9E] 2 1 2 5 + +
15[8H] 3 3 1 7 + +
15[11F] 4 3 3 11 + +
16[7F] 2 2 3 7 + +
16[8A] 3 3 4 11 + +
Spot Deconvoluted code Interaction confirmed
Galactose 
dependence
Deconv. 
score
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A 96-spot array was created with colonies from 46 deconvoluted, partially deconvoluted and 
not deconvoluted spots. Colonies were passed to CSM –HIS –TRP –ADE –LEU plates 
containing sucrose and galactose or glucose. True interactions should occur in plates containing 
galactose but not glucose. A second yeast-two-hybrid assay with lariat ligands from 
deconvoluted spots expected to be reproducible was performed against the eight targets pooled 
in the screening of a combinatorial lariat ligand library with PI-deconvolution. The variable 
region of the lariat ligand was re-cloned into the prey vector by homologous recombination in 
yeast. Colonies were plated in galactose and sucrose CSM –HIS –TRP –ADE –LEU plates. 
Deconvolution score is estimated only for deconvoluted spots; not deconvoluted (ND) or 
partially deconvoluted (PD) do not ajust to this criterium.  
 
 
 
Figure 5.12. Phylogenetic tree of deconvoluted lariat ligands.  
 
The confirmed deconvoluted hits and their confirmations were DNA sequenced, and a 
phylogenetic tree was generated using the region of seven amino-acids that forms the lariat 
motif. The sequences shown interact with the GEF domain of BCR in a yeast-two-hybrid assay, 
with the exception of 4[11B] that interacts with SH3, 11[9A] that interacts with SH1 and both 
6[4H] and 7[10D] that interact with the FABD domains of ABL. 
 
5.9. β-Galactosidase assay to measure the strength of the interaction of the 
confirmed lariat ligands 
 In order to measure the affinity of the different confirmed positive hits for their targets, 
we performed a β-galactosidase assay. The β-galactosidase assay measures the strength of the 
interaction between a lariat and their target. It is based on the spectrophotometric detection of 
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ortho-nitrophenol, a compound formed after the hydrolysis of ONPG (ortho-nitrophenyl-β-
galactoside) by β-galactosidase. It measures the amount of β-galactosidase expressed in yeast 
cells, as a consequence of the interaction of the lariat with its target and thus the activation of 
the yeast-two-hybrid reporters. It is a semi-quantitative assay. β-galactosidase is one of the 
three reporters that we employed in the yeast-two-hybrid assay, encoded by the LacZ gene. A 
liquid β-galactosidase was performed with all the confirmed deconvoluted positive hits. 
Differences were detected, which provided good criteria for selecting lariat ligands for further 
analysis (Figure 5.13). For all the experiments performed, the values were normalized to the 
strength of interaction between the RIZ1 and the lariat ligand 6-49. Even though most of the 
isolated lariat ligands did not show the same strength of interaction as RIZ1 and 6-49, some 
positive hits presented a remarkable strength of interaction measured by the β-galactosidase 
assay, around 3– and 2– fold higher than the reference. This is the case of 4[11B] and 5[12H], 
6[5A] and 9[5G] lariat ligands. 4[11B] interacts with the SH3 domain of BCR-ABL according 
to the yeast-two-hybrid assay, whereas the other isolated lariat ligands bind the GEF domain of 
BCR-ABL with high affinity. Twenty-three lariat ligands performed below the threshold 
imposed by the reference. 
 
5.10. Screening of a combinatorial lariat ligand library with single targets 
 From the PI-deconvolution screening, we isolated a large number of positive hits that 
interacted with the GEF domain (twenty-six), in comparison with the positive hits that 
interacted with SH3, SH1 or FABD domains of BCR-ABL. The GEF domain of BCR might be 
more prone to bind lariat ligands than the other domains from BCR-ABL. In order to test this 
hypothesis, we screened a combinatorial lariat ligand library (based on the Ssp-Ssp Intein 
scaffold, the same library used for the PI-deconvolution screening) against individual targets 
using the yeast-two-hybrid assay, and counted how many positive hits appeared (Figure 5.14). 
Positive hits were selected in galactose and sucrose CSM –HIS –TRP –ADE –LEU + X-Gal 
plates. More positive hits were isolated against the GEF domain than against other domains, 
which supports the idea that the GEF domain is prone to interact with lariat ligands. However, 
the differences are not as striking as they were for the PI-deconvolution screening, for which 23 
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positive hits interacted with the GEF domain, and only one positive hit interacted with the SH3 
or the SH1 domain.  
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Figure 5.13. β-galactosidase assay with confirmed deconvoluted lariat ligands.  
The values from the liquid β-galactosidase assay were calculated as Miller units (see methods), 
and normalized to a reference interaction, the interaction between RIZ1 and the 6-49 lariat 
ligand. The value of this interaction was considered 100%.   
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Figure 5.14. Number of positive hits isolated after a screening of a combinatorial lariat 
ligand library against single BCR-ABL domains. 
 
The four domains of BCR-ABL for which positive hits were confirmed in the PI-deconvolution 
were screened individually against a combinatorial lariat ligand library (Ssp-Ssp intein) using 
the yeast-two-hybrid assay. A total of 25 million diploids were plated on galactose and sucrose 
CSM –HIS –TRP –ADE –LEU +X-Gal plates and the number of positive hits were determined.  
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6. DISCUSSION 
 
 Protein ligands that interact with a specific target protein can be developed. They can 
block its function or prevent it from associating with other protein partners. Protein ligands can 
be used in a wide array of applications, ranging from diagnostics to the study of cell signaling 
and as leads to identify small-molecule inhibitors. They can be isolated by artificial means from 
combinatorial libraries using the yeast-two-hybrid assay. However, the assay detects false 
positives, which imposes the need to confirm identified interactions of the target protein and the 
protein ligand. To do so, the plasmid expressing the protein ligand must be isolated and 
reinserted in a yeast prey strain, followed by a second yeast-two-hybrid assay with the bait it 
originally interacted. This is a time-consuming and labor-intensive task, especially when dozens 
of positives hits have to be reconfirmed.  
 Pooling samples can dramatically improve the screening of biological libraries, such as 
protein ligand, cDNA and genomic libraries. Pooling designs dictate how members of the 
library or the targets must be distributed in different pools. Instead of testing an entire library, 
or individual samples, pools are tested, and the goal becomes to detect a specific event in the 
pools, which in our case is a protein-protein interaction. Certain pooling designs can detect 
errors, or false positives, a very useful property when screening a combinatorial protein ligand 
library. We chose to adapt the PI-deconvolution pooling design to screening of combinatorial 
libraries (Jin et al., 2006). According to the conditions imposed by PI-deconvolution, we aimed 
to screen a combinatorial protein ligand library against eight proteins, seven target domains 
from BCR-ABL and one negative control (LexA). BCR-ABL is an oncogene that results as a 
consequence of the fusion of ABL and BCR through chromosomal rearrangements. The 
chimera has been shown to be responsible for most cases of chronic myelogenous leukemia 
(Ren, 2005). The seven domains that we chose to screen are involved in the pathogenesis of 
BCR-ABL or play a role in the unregulated kinase activity of ABL.  
 Our screening of protein ligand libraries using the yeast-two-hybrid assay consisted of a 
combination of a matrix-based screening and the PI-deconvolution design. We determined the 
optimal conditions to perform a screening using a combinatorial protein ligand library. The 
yeast-two-hybrid assay fails to detect interactions when an interacting bait and the prey are 
diluted in a pool of non-interacting strains. In our case, the baits were pooled according to PI-
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deconvolution, and the preys were randomly pooled. Using the interaction between  RIZ1 and 
the protein lariat ligand 6-49 as a reference, we determined the probability of detecting an 
interaction when the bait and the prey are diluted serially, from 2-fold to 1000-fold. This 
probability was found to decrease dramatically when the interacting preys are diluted more than 
100-fold. These results were consistent when RIZ1 was pooled according to PI-deconvolution. 
Probably, as the interacting bait and prey are diluted, the chanc es of mating with each other 
decrease because they can mate to a non-interacting strain, thus not forming the diploid in 
which the bait-prey interaction would occur. Furthermore, it is likely that the replicator tool 
fails to transport all the possible combinations of diploids formed in one spot, and in this way 
the diploids in which the interaction occurs are not taken to the next plate where the yeast-two-
hybrid selection occurs. 
 We performed a screening of a protein ligand combinatorial library with targets pooled 
according to PI-deconvolution. Seven domains of BCR-ABL were cloned as LexA DBD 
fusions in the pEG202 plasmid, namely the Coiled-coil (CC), a peptide containing the tyrosine 
Y177, Guanidine exchange factor (GEF), SH3, SH2, Tyrosine kinase (SH1) and F-Actin 
binding domain (FABD). These seven targets, along with an additional negative control, the 
LexA DBD alone, were pooled according to PI-deconvolution in six pools; every pool 
contained four targets. Using the yeast-two-hybrid assay, all pools were screened against a 
combinatorial protein ligand library. The scaffold of the library is an Ssp-Ssp engineered intein 
that displays lariat peptides; the library contains seven randomized positions in the lariat. The 
library was arrayed as spots containing approximately 750 different members. Every spot was 
tested against each of the six pools. Approximately one million different protein ligands were 
screened against every pool. After performing the yeast-two-hybrid selection, only the positive 
interactions from pools that fully deconvoluted are expected to be true bait-prey interactions. 
The interactions from these positive hits were reconfirmed, showing the utility of the PI-
deconvolution pooling design.  
 The majority of the isolated positive hits interacted with the GEF domain of BCR. For 
the remaining positive hits, one positive hit interacted with the SH3 domain, another with the 
SH1 domain, and two against the FABD domain. The sequence of the seven amino-acids that 
constituted these lariat ligands was obtained, and the strength of the interaction between every 
protein ligand and its target was measured using a spectrophotmetric β-galactosidase assay. 
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Finally, we developed a criterion to classify all the isolated positive hits, referred to as the 
deconvolution score. From the deconvoluted positive hits, those with low deconvolution scores 
are likely false positives, whereas all the positive hits that were deconvoluted and showed high 
deconvolution scores were reconfirmed for their detected interactions.   
 Altogether, we have shown that PI-deconvolution can be adapted to the screening of 
protein ligand combinatorial libraries. Our conditions can be adjusted to any screening, given 
the parameters we evaluated, such as the probability of detecting a positive hit when the 
interacting bait and prey are diluted. This suggests the number of targets that can be pooled (8, 
16, 32, 64, etc) and the number of library members per spot, which ultimately dictates how 
many plates need to be constructed and what fraction of the combinatorial library can be 
screened. Furthermore, the positive hits whose interaction with their predicted target was 
reconfirmed were deconvoluted and showed high deconvolution scores. Future screenings 
could only focus their attention on those positive hits that show high deconvolution scores, 
without the need to reconfirm their interactions by tedious molecular biology methodologies. 
Although performing a screening using PI-deconvolution requires extensive planning and its 
set-up is labor-intensive, on the long term it offers more benefits than conventional approaches. 
Our strategy is an effective way to overcome the limitation of the appearance of false positives 
in the yeast-two-hybrid assays. Furthermore, we performed a screening of the Ssp-Ssp intein 
combinatorial library using the conventional approach, against the four BCR-ABL baits for 
which we isolated confirmed deconvoluted positive hits in the PI-deconvolution screening. This 
screening was important because it allowed a comparison of the performance of PI-
deconvolution applied to the screening of protein ligand combinatorial libraries. 
 Using the PI-deconvolution approach, we isolated a set of lariat ligands against different 
domains of BCR-ABL: GEF, SH3, SH1 and FABD domains. After our single-bait screening we 
isolated more lariat ligands, against the same BCR-ABL domains and the SH2 domain. They 
are potential interactors with BCR-ABL, which might inhibit its oncogenic potential or alter the 
phenotypes it induces. We generated a phylogenetic tree with the isolated lariats that shows 
well defined clusters of sequences, according to the domain with which they interact. The 
sequence similarity of certain ligands suggests they must interact with the same region of a 
target. 
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 The fact that more lariat ligands were isolated against the GEF domain of BCR than any 
other domain of BCR-ABL is surprising. In the only study that has reported the isolation of 
protein ligands (peptide aptamers) that interact with a GEF domain (Schmidt et al., 2002), they 
found three different inhibitors of the GEF domain of Trio. Their sequences are not similar to 
the sequences of the lariat ligands that we report in this study, although the TrxA scaffold is 
different from the Ssp-Ssp engineered intein that displays lariat peptides. They did not mention 
how many positive hits they found in their study, hence there is no evidence to support that 
GEF domains are highly prone to interact with peptides. Another study reported the isolation 
nucleic acid aptamers against the GEF domain of Cytohesin 1 (Mayer et al., 2001). After 
several rounds of selection of ligands, they reported only five sequences of RNA aptamers that 
bind to a GEF domain. The other known inhibitor of a GEF domain is the fungal small 
molecule inhibitor Brefeldin A (BFA), which binds to GEF domain of Arf proteins in the GDP-
bound state (Renault et al., 2003). GEF domains are flexible molecules that can cycle between 
a GDP-bound and a GTP-bound state. One possibility is that the lariat ligands we have isolated 
interact against different conformations of the GEF domain, either the GDP- or the GTP- bound 
states.  
 Relatively few lariat ligands against docking domains such as the SH3 and SH2 
domains of ABL were isolated in comparison to the GEF domain. One would expect that these 
domains, whose main purpose is to bind other proteins, would be highly prone to interact with 
other molecules. For instance, in our PI-deconvolution screening of a combinatorial protein 
ligand library only one lariat ligand was isolated against the SH3 domain and none against the 
SH2. When we conducted a single-bait screening against these domains, we detected more 
lariat ligands that interacted with the GEF domain than the other BCR-ABL domains. This is 
evidence that supports that the GEF domain of BCR is more prone to interact with lariat ligands 
than the other BCR-ABL domains screened. The discrepancies between the lariat ligands 
isolated from the PI-deconvolution screening and the single-bait screening might not be related 
to the structure of the domains but rather the conditions under which the screenings were 
performed. We assumed that all the baits from every pool would be present in equal amounts, a 
ratio 1:1:1:1. It is possible that some baits grew faster than others and would become the 
majority of the baits in the pools, which would give them an advantage over the other baits for 
finding an interactor.  
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 The question arises whether it is better to perform a PI-deconvolution or a single-bait 
screening to isolate protein ligands from a combinatorial library. It should be noted that the 
conditions under which we performed a PI-deconvolution were entirely manual, and this type 
of screening would be more useful if automated conditions were used. This way, a larger library 
size and more targets could be screened at one time, avoiding the need to re-confirm the 
observed interactions. The deconvolution score is a very practical parameter to validate the 
observed yeast-two-hybrid interactions.  However, we did isolate more lariat ligands in the 
single-bait screening, in comparison to the PI-deconvolution screening. If only a limited 
number of targets will be screened, it might be better to perform a single-bait screening. If a 
considerable number of targets will be screened, more than eight, and there are robotic 
equipment in the laboratory, PI-deconvolution would offer excellent benefits.  
   We performed a PI-deconvolution screening of a protein ligand combinatorial library 
under one set of conditions, namely pooling eight baits, one million library members and an 
Ssp-Ssp engineering intein lariat ligand library. It would be interesting to evaluate the 
performance of PI-deconvolution screening using more complex conditions, like pooling more 
targets, or using a different scaffold for the creation of the combinatorial library. Data from 
more screenings will support the usefulness of the deconvolution score parameter, to determine 
if it can determine with confidence whether a positive hit will be reconfirmed or not. 
Altogether, we established the appropriate conditions to screen a protein ligand combinatorial 
library using the PI-deconvolution pooling design with seven domains of BCR-ABL, and 
established parameters to evaluate future screenings. Our findings should facilitate the isolation 
of protein ligands that interact with other targets of interest. Further studies may focus on 
expanding the number of targets that can be screened at the time, with the use of robotic 
equipment. The ideal scenario would be to isolate a protein ligand that alters the function of 
every protein of the genome of an organism, in order to evaluate the function of every protein. 
Additionally, the approach we employed can be used to adapt PI-deconvolution to the screening 
of combinatorial libraries with other methodologies, such as phage-display.   
 We screened a protein ligand combinatorial against a variety of targets, ranging from a 
short peptide stretch (Y177) to a tyrosine kinase domain to docking domains (SH3 and SH2).   
We determined the amino-acid sequence of a variety of lariat ligands that interact with domains 
of BCR-ABL using the yeast-two-hybrid assay. It will be very interesting to determine whether 
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there lariat ligands interact with BCR-ABL with another technique that detects protein-protein 
interactions and also whether they can inhibit ABL kinase activity or inhibit its interaction with 
docking domains. Coimmunoprecipitations and surface plasmon resonance could be used to 
determine if the isolated lariat ligands do interact with their target, among other methodologies 
available. It will be also of interest to determine whether these lariat ligands can have an effect 
on downstream signalling pathways. For the GEF domain, it will be interesting to determine if 
it can alter the motility of BCR-ABL+ cell lines. Also will be interesting to determine if these 
lariat ligands can inhibit the proliferation of BCR-ABL+ CML cell lines; in such a case, they 
could lead the discovery of small-molecule inhibitors of BCR-ABL, which along with Imatinib 
would constitute a very strong and effective therapy against CML.  
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